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1 AIM OF THIS THESIS 
The aim of this work is to evaluate the efficacy of the percutaneously inserted metallic 
self-expandable Wallstent endoprosthesis in malignant biliary obstruction. Six years of 
experience with the Wallstent and the results of randomized trials justify an evaluation 
of the current status of the biliary Wallstent endoprosthesis. 
The problems encountered with conventional plastic endoprostheses in the palliative 
treatment of malignant obstructive jaundice are discussed first (Chapter 2). The major 
problem with plastic stents is reduced patency caused by stent blockage. Possible 
solutions to prolong patency. which predominantly concern minor changes in stent 
diameter and stent material, are described. A landmark was the introduction of the 
expandable metal stent in the second half of the 1980s. The revolutionary design of the 
metal stent was promising and a more fundamental and improved progress in stent 
patency was anticipated. 
Most experience with metal stents in malignant biliary obstruction concerns the Wall-
stent endoprosthesis. The clinical results with the Wallstent are the subject of this thesis. 
The early experiences are reported first (Chapter 3). The results of the Wallstent in 
hilar and distal strictures are subsequently described separately, as these involve 
different study populations (Chapters 4 and 5). Complications related to the use of the 
Wallstent are discussed, with emphasis on technical aspects of the use of the Wallstent 
in percutaneous stenting (Chapter 6). Finally, the place of the Wallstent in the treatment 
of malignant biliary obstruction will be defined (Chapter 7) and the important issues of 
this work are summarized. 
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2 INTRODUCTION 
2.1 Introduction 
Obstructive jaundice is a major symptom of cancer involving the biliary system. 
Pancreatic carcinoma is the most common cause; bile duct carcinoma, gallbladder 
carcinoma and metastatic disease are other frequent causes of malignant biliary obstruc-
tion. In 1989 almost 30.000 new cases of pancreatic carcinoma were diagnosed in the 
USA [1]. Gallbladder carcinoma occurred in approximately 10,000 patients and bile 
duct carcinoma in 4,500 cases [2,3]. In the Netherlands in 1992, 109 males and 114 
females per 1,000,000 inhabitants died of pancreatic cancer while 18 males and 42 
females per 1,000,000 inhabitants died of biliary tract cancer [4]. 
Curative surgery of malignant distal or hilar biliary strictures is possible in only a 
minority of patients [1,5-13]. In the remaining patients palliative biliary drainage should 
be considered to treat jaundice and the often accompanying pmritus [14]. Obstructive 
jaundice has profound systemic effects, such as on renal function and immunity. and 
may present as or evolve to cholangitis [15-25]. Several palliative treatment modalities 
should be considered: endoscopically inserted biliary endoprostheses, percutaneous 
biliary drainage or surgical biliary bypass. 
2.2 Palliative biliary drainage 
Surgical or /101l-surgicallrealmelll 
Surgical biliary bypass is one of the three palliative treatment modalities available in the 
management of patients with malignant obstructive jaundice. It is, however, associated 
with a considerable morbidity and mortality rate. A literature review of 20 years of 
palliative surgery of pancreatic carcinoma disclosed an overall surgical bypass mortality 
rate of 14% in the 1980s [26]. The ranges were, however, wide and the results 
improved according to more recent studies. Comparison of surgical bypass, percuta-
neous stents and endoscopic stents in this review disclosed comparable drainage success 
rates, but more early and less late complications in surgical bypass [26]. Recent studies 
on surgical bypass in pancreatic carcinoma report postoperative morbidity in 20-30% of 
cases [27-29]. A recent retrospective study of surgical biliary bypass and endoscopic 
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plastic endoprostheses at our institution advocates palliative endoscopic stenting of 
malignant pancreatic strictures in patients surviving less than six months and surgical 
bypass in patients expected to survive more than six months [30]. The patients treated 
by endoprostheses wete significantly older than in the other group. Some surgeons 
prefer the surgical placement of tubes or stents which is, however, associated with a 
thirty-day mortality of approximately 10-15% [31]. Palliative surgery of hilar strictures 
has a mortality rate of approximately 20% with, however, wide ranges of 5-33% [5,32-
34]. A retrospective study reports higher hospital mortality in non-surgical treatment 
compared to surgical bypass [33]. The small non-surgical group was, however, diverse-
ly treated and had significantly more concomitant medical problems before treatment. 
The thirty-day mortality of surgically placed tubes in patients with malignant hilar 
strictures is approximately 20% [5,35,36J. 
Comparison of the treatment modalities in this way is, however, influenced by patient 
selection. Debilitated patients are often considered unfit for surgery and are therefore 
referred for non-surgical drainage. Several randomized trials have been perfonned 
comparing surgical bypass and non-surgical, predominantly endoscopic, endoprostheses 
in pancreatic carcinoma [37-43]. These series included patients treated by 
cholecystostomy or choledochoduodenostomy. A randomized study on percutaneous 
endoprostheses and surgical bypass in inoperable pancreatic carcinoma demonstrated 
successful drainage in all patients [37]. The overall early complication rates were 
comparable but, with increasing percutaneous experience, less complications occurred in 
patients treated by percutaneous stenting. Thirty-day mortality and procedure-related 
mortality were less with percutaneous stents. The median hospital stay was significantly 
less with percutaneous stents, although no longer significant when readmissions for 
recurrent jaundice and duodenal obstruction were taken into account. Several 
randomized series on surgical bypass and endoscopic endoprosthesis demonstrate their 
equal effectiveness in drainage [38-42J. The early complication rate and thirty-day 
mortality were somewhat ltigher in patients treated by surgery. Post-procedural hospital 
stay tended to be longer in surgical treated patients, but readmissions occurred more 
often in the endoscopically treated group due to stent blockage. 
Malignant tumors causing obstructive jaundice may also cause duodenal obstruction. 
The occurrence of duodenal obstruction requiring bypass surgery is influenced by the 
type of stricture and the survival of the patient. In a series of 1,153 endoscopically 
treated patients with malignant obstructive jaundice, surgical bypass was necessary in 
7.5 % of the patient population, varying from 2.4 % in metastatic disease to 23 % in 
ampullary strictures [44]. In pancreatic carcinoma, 9% of patients needed surgical 
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bypass while some other endoscopic series reported a lower incidence in pancreatic 
carcinoma [45-47]. Two reviews of surgical series after biliary bypass alone for 
pancreatic carcinoma report an average of 17-21 % needing gastrojejunostomy at a mean 
of 8.6 months [1,26]. The lower incidence in the endoscopic series is probably due to 
patient selection, as patients are excluded from endoscopic drainage when duodenal 
stenosis is expected shortly after intervention. Patient survival is not significantly 
increased by either form of palliative drainage [48]. 
The introduction of non-surgical biliary drainage has changed the management of 
patients with inoperable biliary obstruction. In most hospitals, poor operative candidates 
and patients with inoperable cancer will be treated by non-surgical drainage. Reasonable 
operative candidates in whom unresectability cannot be proved definitely preoperatively 
and patients with duodenal obstruction are candidates for surgery. 
Percutaneous or elldoscopic draillage 
Numerous non-comparative reports have been published describing the results of the 
endoscopic or percutaneous technique. Comparison is hampered by differences in 
patient populations, definitions of complication and success, and improvement in results 
due to continuous technical improvements. Comparison of recent data indicates no 
major differences in success and complication rates in distal biliary strictures 
[44,49,50]. In hila I' strictures the overall success and complication rates of the studies 
have wider ranges, with a somewhat higher success rate and lower complication rate in 
percutaneous stenting [44,51-54]. A retrospective comparative study, including patients 
with catheter drainage, has reported preference for the percutaneous teclmique in hilar 
strictures, as eady complications were less [51]. More solid conclusions might, 
however, be drawn in randomized trials. One such series has been performed [55]. The 
study population included patients with distal and hilar strictures. Stent insertion was, 
although not statistically significant, slightly more successful with endoscopic stents. 
When successful drainage was included as additional parameter the difference became 
significant (61 % versus 81%). Early complication rate and thirty-day mortality were 
higher with percutaneous stents (67% versus 19%, and 33% versus 15%, respectively). 
The occurrence of other early complications, as well as late complications, were 
approximately comparable in both groups. As this study is the only randomized study 
comparing the results of the endoscopic and percutaneous technique it deserves special 
attention, especially as it is often referred to as proof of the superiority of the endo-
scopic technique. Some criticism on this study is, however, justified. The percutaneous 
technique used was not state-of-the-art as no ultrasound guidance was used, while a 
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caliber jump in size between the initial drainage catheter and the stent occurred [56,57]. 
This is probably the explanation for the low placement success rate and remarkable high 
percentage of bleeding and bile leakage. Although more patients with hilar stricture 
were randomized to the endoscopic technique. no reference was made to the type of 
hilar stricture and, therefore, the complexity of the strictures was ignored. The authors 
later reported comparable extent of hilar strictures in both groups, but did not expand 
on this statement [58,59]. One of the authors of this randomized trial stated: "the results 
of a randomized study thereby apply to the cohort of patients fitting the entry criteria, 
which may be only a small part of the spectmm, and only within the institution con-
cerned" [60]. For several reasons it therefore seems not justified to use this randomized 
trail as the definite proof of the superiority of the endoscopic technique. 
When the percutaneous or endoscopic technique or both fail, an alternative treatment is 
the combined percutaneous-endoscopic procedure or Rendez-vous procedure [61-63]. 
With this technique a percutaneously inserted guide wire is passed through the stenosis 
and grasped by the endoscopist who brings it outside the mouth. Control of both ends of 
the guide wire forms a stable track facilitating railroading of a stent. The combined 
procedure is often successful in cases not amenable to other non-surgical therapy with, 
however, an additional complication rate [64-66]. As with other new therapeutic techni-
ques a learning curve exists, especially concerning too vigorous stent insertion resulting 
in liver parenchymal damage [67,68]. Other combination treatments have also been 
proposed, such as a fluoroscopically guided retrieval basket instead of employing an 
endoscope [69]. 
The choice between the endoscopic and percutaneous technique is dominated by 
diverging reported results and local circumstances. Endoscopic retrograde 
cholangiopancreatography (ERCP) will be part of the diagnostic work-up of patients 
with malignant distal biliary strictures. As endoscopic stent insertion can be performed 
in the same session and the results of percutaneous and endoscopic techniques are 
comparable, endoscopic stent insertion is the treatment of choice. When this fails, 
percutaneous stent insertion is the equal valuable alternative. In patients with hilar stric-
tures, the choice is more debatable and often dictated by local circumstances. Overall 
published results indicate some preference for percutaneous stenting. In case of failure 
of one of the techniques the other technique, or the combined procedure, should be 
considered. 
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2.3 Percutaneous biliary drainage 
History 
Percutaneous transhepatic puncture of the intrahepatic biliary ducts was perfOimed 
sporadically in the first half of this century. The first report of percutaneous transhepa-
tic cholangiography dates from 1937 [70]. In these sporadic cases only diagnostic proce-
dures were perfOlmed. The development of fluoroscopy and image intensification and 
the use of a cannular sheath facilitated the percutaneous procedure, which, therefore, 
became more popular in the 1950s and 1960s [70]. It was performed preoperatively 
with the sheath in place as external drainage before surgery. Leaving a sheath or cathe-
ter in place also prevented intraperitoneal bile leakage [71-73]. Kaude et al in 1969 
were the first to describe prolonged drainage with this technique as palliative treatment 
of a malignant stricture [74]. This teclmique has, however, the disadvantage of 
prolonged external bile loss with its metabolic consequences, such as hypotension. A 
landmark in the development of percutaneous drainage was reported in 1974 by Molnar 
and Stockum who advanced a multiple side hole catheter through a stenosis, thereby 
establishing internal bile drainage [75]. As early experience was overshadowed by a 
considerable number of especially inIectious complications (approximately 40%) further 
refinements were developed in the following years, giving better results [76-86]. Chan-
ges in puncture technique and catheters and the use of ultrasound guidance are examples 
of the progress in percutaneous biliary drainage [56,73,87]. 
The percutalleous techllique 
Parenteral antibiotic prophylaxis is given 12 h before and after each procedure [88]. 
Bleeding and clotting times should be checked and corrected when indicated [89]. The 
procedure is perfonued under sterile conditions with the ultrasound transducer wrapped 
in a sterile sleeve. Local anesthesia is established by lidocaine, while midazolam and 
fentanyl are used as systemic sedative and analgesic. Both midazolam and fentanyl have 
the advantage of rapid onset of action and short half-life [89]. A pulse oximeter and an 
automatic blood pressure monitor may be used to control oxygen saturation and blood 
pressure [90,91]. Some have advocated epidural anesthesia in percutaneous biliary inter-
vention [92]. 
Use of the anterior approach to the left hepatic duct is preferred at our institution. This 
,nterior approach avoids the risk of a traospleural puncture while a left-sided catheter 
gives less patient discomfort and has a reduced dislodgement risk [56,73,93-96]. The 
latter is also important for patients treated by endoprostheses as this is, in our institu-
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tion, mostly performed as a two-stage procedure, especially in hilar strictures. A cathe-
ter will, therefore, be in place after the first procedure. A right lateral, preferably sub-
costal, ultrasound-guided approach may be indicated in hilar strictures when left hepatic 
lobe atrophy exists, or when multiple intubations are necessary in hilar disease. Ascites 
is a relative contra-indication for percutaneous drainage. Leakage of ascitic fluid along 
the catheter may occur and drainage of infected bile will cause peritonitis. 
First, an appropriate bile duct will be localized by ultrasound and a puncture route will 
be chosen. An ultrasound transducer (3.5 MHz) with a sterile puncture adaptor is used. 
A skin incision is made at an appropriate site and a short, stiff 18 gauge needle [Spino-
can, B Braun Melsungen AG, Germany] is inserted through the puncture adaptor and 
the skin. This needle prevents bending of the 22 gauge echo-tip design Chiba puncture 
needle [Cook Europe AlS, Bjaeverskov, Denmark] due to movements between the skin 
and the transducer. During breath hold the Chiba puncture needle is inserted into the 
biliary system. Correct position is confirmed by bile discharge after removing the stylet 
of the Chiba needle. In distal strictures a more central segmental duct can be punctured, 
but in hilar strictures a more peripheral entry should be used to allow for adequate over-
stenting and guide wire and catheter manipulation. A 0.046 cm (0.018 inch) Cope 
mandril stainless steel guide wire with platinum tip [Cook Europe AlS, Bjaeverskov, 
Denmark] is introduced through the Chiba needle into the biliary duct. This action is 
observed by ultrasound. The puncture needle is removed and a 22 gauge needle with a 
preloaded 7-F teflon sheath [Neff percutaneous access set, Cook Europe AlS, Bjae-
verskov, Denmark] is introduced over the guide wire. The sheath will be pushed over 
the guide wire into the bile duct when the needle is inside the bile duct. The needle and 
the guide wire are withdrawn and, after aspiration of bile, water-soluble contrast agent 
is injected into the biliary system. Radiographs of the stricture will be made to docu-
ment the stricture and to decide which treatment is most appropriate. In patients with 
cholangitis only external drainage will be established. In these cases the procedure will 
be stopped after an 8-F pigtail catheter [Cook Europe AlS, Bjaeverskov, Denmark] has 
been left for external drainage. Further manipulations will be performed in a second 
session when the cholangitis has disappeared. In all other patients an attempt will be 
made to pass the stricture at the initial session. An 0.035 inch hydrophilic-coated angled 
tip guide wire [Glide wire, Terumo Corporation, Tokyo, Japan], a 5-F cobra-head 
shaped angiographic catheter [Cordis Europe NV, Roden, The Netherlands] and a 0.035 
inch modified Amplatz extra stiff guide wire [Cook Europe AlS, Bjaeverskov, Den-
mark] facilitate this procedure. An external 8-F pigtail catheter will be used in case of a 
failed attempt. 
16 
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After several days the second stage of the procedure will be performed. When stricture 
passage has not been established during the initial procedure the second session will 
start by attempting to establish stricture passage. This attempt will often be successful. 
Because the external drainage has reduced the diameter of the prestenotic dilated bile 
duct, the lumen will be better matched to the stricture diameter facilitating guide wire 
and catheter passage. After stricture passage an endoprosthesis or catheter can be 
introduced. For the technique of percutaneous plastic endoprothesis insertion one is 
referred to the literature, while metal stent insertion is described in this chapter (2.6) 
[73]. 
In hilar strictures more than one catheter or endoprosthesis may be needed necessitating 
multiple punctures and stricture passages. The choice to perfonn multiple drainage 
procedures is influenced by several factors, such as the clinical condition of the patient, 
the life expectancy and the anticipated success of the procedure. Incomplete drainage 
will often be sufficient to treat distressing symptoms such as pruritis. Bilateral catheter 
drainage has been perfOimed through a single percutaneous approach. Bilateral drainage 
by endoprostheses inserted through a single tract will, however, hamper reintervention 
[97-99]. A Y-shaped drainage catheter which can be inserted through a single percu-
taneous tract has been developed [99]. It functions as an endoprosthesis with a subcu-
taneous button. 
A percutaneous access to the biliary tree allows several diagnostic and therapeutic 
procedures such as biopsy, cholangioscopy, intraluminal ultrasound or intraluminal 
radiotherapy [100-105]. In selected cases, an alternative percutaneous approach can be 
used such as a cholecystostomy or a transjejunal route [106,107]. 
2.4 Plastic endoprostheses 
In the 1970s and early 1980s percutaneous catheter drainage had become an established 
method of palliative drainage of malignant obstructive jaundice. One aspect of tItis treat-
ment, however, namely the permanent presence of a catheter, was considered a major 
disadvantage [108]. The catheter acts as a constant reminder of the underlying disease 
while it thereby requires daily care. Tltis prompted the use of a tube crossing the stric-
ture without external continuation: an endoprosthesis. 
The ftrst reports on the use of a percutaneously inserted biliary endoprosthesis were 
published at the end of the 1970s [109-111]. The first endoscopic report was published 
one year later [112-115]. Already early in the use of endoprostheses in non-surgical 
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bilialY stenting major drawbacks became clear [116,117]. Early cholangitis occurred in 
up to 40%, while stent blockage by sludge occurred in 50-90 days implicating frequent 
reintervention. Occlusion of plastic endoprostheses is often clinically presented as 
cholangitis or jaundice [118]. To reduce the incidence of stent blockage experimental 
and clinical research has been done in order to identify factors contributing to stent 
blockage. 
Research reslIlis 
Analysis of the contents and surface of occluded stents has elucidated the mechanism of 
stent blockage. The initial event in stent blockage is bacterial adherence to absorbed 
proteins on the stent surface, with subsequent biofilm formation and bile crystals 
deposition [44,119-121]. Other factors such as duodenal reflux of food fibers add to this 
phenomenon [44,119,122,123]. Several stent characteristics, such as stent surface 
material, surface area and especially inner diameter, have been recognized as significant 
factors influencing the process of stent occlusion [108]. 
One of the methods to reduce stent blockage might be to prevent or reduce bacterial 
adherence by changing stent materials, or the introduction of a surface coating. Howe-
ver, contradictional experimental results have been reported on the influence of different 
stent materials on stent patency [124-127]. Differences in experimental design, such as 
using single or multiple bacteria strains, renewal of perfusion bile and stent diameter are 
major factors influencing these results. A small clinical comparative study on antibiotic-
coated stents versus conventional stents did not demonstrate any advantage of antibiotic-
coated stents [128]. An in vitro study has reported decreased bacterial adherence to 
silver-coated stent material [129]. Hydrophilic polymers in hydrogel coating might be 
useful, as less protein adherence is to be expected [108,129]. The high water content of 
the gels makes them, however, intrinsically weak [44]. Oral aspirin and doxycycline 
administration causes a modest decrease in sludge formation [130]. Surface smoothness 
influences patency. A 7-day in vitro study of the ultrasmooth polymer Vivathane 
demonstrated inhibition of bacterial growth and sludge fonnation [131]. Artificial 
defects created on the surface of this stent allowed bacterial adherence only in the area 
of surface irregularity, indicating the importance of surface smoothness. 
More agreement exists in the experimental work on the relationship between stent 
diameter and stent patency. This has demonstrated higher bile flow and relatively less 
incrustation with larger inner diameter stents [124,125,132,133]. Clinical endoscopical 
studies give conflicting results, probably reflecting the difference in study populations 
and type of stents used, as well as the multifactorial mechanism of stent blockage [134-
18 
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139]. Although these clinical studies are inconclusive the majority of the studies report 
longer patency in larger diameter stents. This, together with the experimental findings 
and the experience of many radiologists and endoscopists, favor the use of stents of at 
least lO-F diameter. Some have advocated even larger stent diameters, such as 20-F 
[140,141]. The use of large diameter stents is, however, limited by patient discomfort, 
procedure time and increased costs. Also the risk of complications is expected to 
increase [108]. Thereby patient's anatomy often limits large diameter stenting [108]. A 
large diameter endoprothesis with a subcutaneous port for flushing has been developed, 
but has not gained much popularity [141]. 
Other factors influencing stent patency are the stent configuration, defects in stent 
manufacture and presence of side holes [123,124,127]. Endoprostheses with pigtails or 
sharp taper at the end demonstrate reduced bile flow rate [124]. Stents with side holes 
perform less well, as the bile flow is more disturbed [123,126,127,133,142]. 
Association between some clinical factors, e.g. high bilirubin levels before insertion and 
advanced age, and decreased patency have been reported [143]. 
Another, although less frequent, problem with plastic stents is stent migration. Several 
stent designs have been developed to reduce migration, such as spiral-shaped stents, 
mushroom-tipped stents and stents with anchoring threads to a subcutaneous button 
[144-146]. A simple and effective method is the use of side flaps, as in the Huibregtse 
endoprosthesis [147]. The risk of migration is also reduced using long stents but the risk 
of stent blockage might increase [148-150]. A Y-shaped endoprosthesis was especially 
developed for hilar strictures, but has not gained much popularity outside Germany 
[151]. 
Differences in occurrence of early cholangitis in studies are influenced by the presence 
of cholangitis before the procedure and routine use of antibiotics during placement. 
Antibiotics decrease the risk of cholangitis after manipulation but do not prevent 
occlusion and subsequent cholangitis [130]. 
Recent clinical results 
Technical developments and growing experience have improved the results of 
percutaneous and endoscopic drainage in the 1980s. Evaluation of the current status of 
plastic endoprosthesis should, therefore, be directed to more recent studies using state-
of-the-art techniques. 
Comparing the results of several studies to evaluate the efficacy of the plastic stent is 
hampered by differences in study design and patient popUlation. Patients with !tilar and 
distal biliary strictures are often lumped together as one group, sometimes even 
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combined with patients with benign strictures. The site of the biliary stricture should be 
taken into account as the difficulty of biliary intervention and thereby complication rate 
is increased with hilar strictures. The results of studies should, therefore, be considered 
separately for hilar and distal (non-hilar) strictures. 
Insertion and drainage 
Successful percutaneous or endoscopic endoprosthesis insertion and drainage will be 
achieved in approximately 90-95 % of the patients with a distal stricture 
[43,44,47,49,50,148,152]. In hilar strictures successful percutaneous insertion and 
drainage is accomplished in 90% or more of the patients [50,51,152-154]. Endoscopical 
drainage may be less favorable in hilar strictures with overall success percentages of 53-
93% [44,47,51,52,54,58,117,155-157]. In one endoscopic series insertion of the stent 
was successful in 97%, but included patients treated by the percutaneous technique after 
endoscopic failure [157]. The more complex the stricture the less successful the attempt 
will be [44,157]. The success rate is thereby also influenced by the choice for complete 
or incomplete drainage [54,157-159]. 
Early complications 
Early complications are generally defined as complications occurring within 30 days 
after stent insertion. They occur in approximately 10-20% of the non-surgical treated 
patients, with more complications in patients with hilar strictures than with distal 
strictures [44,50,116,148,152]. The major early complication is cholangitis, occurring 
in 10-15% of the patients with distal strictures and in approximately 20-30% of the 
patients with hilar strictures. The occurrence is influenced by several factors such as 
preexisting cholangitis and the complexity of the stricture [47,157,160-164]. Other 
relatively frequent early complications are stent migration (approximately 1-4%), 
bleeding (approximately 2%), perforation « 1 %), pancreatitis « 1 %), abscess « 1 %) 
and bile leakage « 1 %) [44,50,148,152,157,165-167]. 
Thirty-day mortality rate is approximately 10-20% with a 1-5 % procedure-related 
mortality [41,44,49,51,148,152,153]. 
Late complications 
Late complications of plastic endoprostheses, other than stent blockage, occur in 
approximately 3-5%. This includes stent migration, acute cholecystitis, stent fracture 
and perforation of bile duct or duodenum [44-47,150,168-178]. 
Stent blockage occurs in 20-40% with a median patency of approximately five months 
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in distal strictures and a median patency of approximately three months in hilar 
strictures [44,45,47,152,179]. Patients with hilar strictures have more frequent recurrent 
jaundice than patients with distal strictures. This is predominantly caused by tumor 
progression with subsequent obstmction of segmental radicles. 
Plastic slellls: currelll slal1/s 
Blockage of plastic stents remains, despite much efforts, a significant problem in biliary 
stenting [108,117J. As new types of plastic stents do not give the solution other ways to 
prevent stent occlusion and cholangitis should be found. 
A percutaneous alternative could be to treat all patients with catheters and to abandon 
the endoprosthesis [180,181]. Although catheters require daily care and have their com-
plications they have one major advantage: they are easy to exchange, while blocked 
endoprostheses necessitate a new intervention. A disadvantage of catheters is the perio-
dical catheter exchange to prevent blockage. Patients generally react in one of two ways 
to a catheter [108J. One group sees the catheter as a "life line" and considers the daily 
care of the catheter as their part of the management of their disease. The other group 
sees the catheter as an unpleasant reminder of their impending death. In the former 
group there may be a place for catheter drainage depending on several factors, such as 
life expectancy. 
Another comparable solution that has been proposed is prophylactic endoscopic stent 
replacement [137,182]. This is, however, not a very attractive solution as it may well 
subject a large number of patients with a short life expectancy to an unnecessary proce-
dure. The choice at which interval this stent exchange should occur is crucial. A recent 
report advises to increase the initially used interval of three months to six months [182J. 
A more basic solution which would result in a real progress in stent patency is, 
however, more attractive. This led some workers to look for essentially other types of 
stents to overcome the diameter limitation. The design of metal expandable intravascular 
stents was promising as they seemed to overcome some of the limitations of the plastic 
stents [183-187J. 
2.5 Metal expandable biliary stents 
Corresponding characteristics of all expandable metal stents are the relatively small-
sized delivery systems, the large diameter of the expanded stent, the small surface area 
and fixation against the wall. Differences are the kind of metal used, the delivery 
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mechanism and the way expansion of the stent is achieved - by its intrinsic radial force 
or after balloon dilation. The large diameter and the small surface area are important 
factors preventing stent occlusion by sludge. The fixation against the wall and 
subsequent incorporation in the wall will prevent stent migration. 
The promising characteristics of the expandable metal stents prompted their introduction 
in biliary stenting. The first clinical results were published in 1989 [187-190]. Several 
types of metal stents are available. The most commonly used biliary stents are, in order 
of popUlarity: the Wallstent, the Gianturco stent and the Strecker stent (Fig. 2.1). 
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Figure 2.1 Most commonly used expandable metallic slents for biliary stenting. 
(a) Wallslent. (b) Gianturco slent. (c) Strecker stent. 
c 
The stents can be divided into two main categories: self-expandable and balloon-
expandable. Self-expandable stents deploy by the intrinsic expanding force, while bal-
loon-expanding stents are dilated to their final size by balloon dilation. 
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Self-expalldable metal stellts 
Wallstent 
The Wallstent (Schneider, Billach, Switzerland and Minneapolis, Minn, USA) is a self-
expandable stainless steel alloy stent with a meshlike construction (Fig. 2.1a). The 
filaments of the stent are 0.12-0.14 mm in diameter. The interlocking weave of the 
filaments allows flexibility around curved surfaces. The stent is introduced in 
compressed form loaded on the distal end of a delivery system (Fig. 2.2). The delivery 
system has two coaxially arranged shafts with the stent mounted on the inner shaft. The 
outer shaft has an outer plastic rolling membrame as distal extension compressing and 
elongating the stent. 
~ 
9 10 11 
Figure 2.2 Wallstent loaded on the introduction catheter. (1) Central lumen. (2) Tip. (3) Micropore. 
(4a) Distal radio-opaque marker. (4b) Central radio-opaque marker. (4c) Proximal radio-
opaque marker. (5) Wallstent. (6) Rolling membrane. (7) Inner shaft. (8) Holes in the inner 
shaft. (9) T-Connector. (10) Stainless steel tube. (11) Luer lock injector. (12) Luer stopcock. 
(13) Outer sheath. 
Reprinted with permission of Schneider (Europe) AG/Pfizer, Biilach, Switzerland. 
The percutaneous delivery system has a diameter of 7-F, the endoscopic system a 
diameter of 9-F. A 9-F sheath [Cook Europe AlS, Bjaeverskov, Denmark] is used in 
our institution to facilitate easy access to the biliary system. Correct positioning of the 
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delivery catheter across a stricture is facilitated by radiopaque markers delineating the 
proximal and distal ends of the compressed stent. Sterrt release occurs when pressure is 
applied to the potential space between the outer and inner rolling membrane while 
pulling back the outer shaft. Membrane failure during deployment may occur, therefore 
modifications to prevent this problem were developed [191,192]. A hydromer coating 
between the membranes and the Unistep-system both proved to be successful solutions. 
With the Unistep-system the compressed stent is released by progressive withdrawal of 
an enclosing sheath. With each type of introduction system the distal end of the 
Wallstent opens first, allowing repositioning. The stent shortens considerably (up to 
40%) while expanding [192-194]. The diameter after full expansion is 8-10 mm, the 
available lengths vary from 3.5-10 cm. Balloon dilation to full expansion immediately 
after deployment is not necessary as the radial recoil force of the stent will result in full 
expansion [195]. This can take several days, or even longer [192]. Clinical results of 
the biliary Wallstent will be discussed in the following chapters. 
Gianturco-Riisclt Z-sfent 
The Gianturco Z-stent stent (Cook Europe AIS, Bjaeverskov, Denmark and Cook, 
Bloomington, Ind., USA) is a self-expandable stainless steel stent with a zigzag structu-
re (Fig. 2.1b). The stainless steel wire is 0.08-0.1 mm in diameter. Six zigzag bends 
are soldered together to form a cylinder. It is firmer and has less longitudinal flexibility 
than the Wallsten!. The delivery system requires an entry of at least ll-F. The stent is 
released by withdrawing the enclosing sheath while the pusher is held in place. It tends 
to deploy abruptly and move forward as it deploys. The diameter used in the bile ducts 
is 10 mm, the length of the stent is varied by connecting two or more bodies (of three 
cm each). Several modifications have been performed, such as side-barbs to prevent 
migration and a nylon suture running through the eyelets at each end to control stent 
diameter [188,196,197]. The latter is the Rosch modification which is usually used in 
biliary stenting [197,198]. A relocatable modification of the Gianturco stent has also 
been developed [199]. The Gianturco stent has the largest radial force of the commonly 
used biliary stents. Several clinical studies on biliaty Gianturco stents have been 
published [188,189,200-204]. A series of 16 patients with malignant strictures reports 
on eight patients with reobstruction with a mean patency of 5.25 months (range three 
weeks-eight months) and one patient with stent migration after 24 hours [190]. The 
majority of the patients in tltis series had a distal stricture. The rather disappointing 
results are propably caused by the large mesh, allowing tumor ingrowth [188,200]. 
Another series including 16 patients with, predominantly hilar, malignant strictures has 
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shown better results with a 6% reobstruction rate after six months. Two other patients 
possibly also had reobstruction with therefore possible increase of the reobstruction rate 
to 19% [188]. An extel15ion of this study reports on 100 patients including 46 patients 
with malignant obstruction, all but one with hilar strictures [205]. Reobstruction 
occurred in seven of the 46 patients (15%). Five cases (24%) of reobstruction after a 
median interval of 15 weeks occurred in a study of twenty-one patients with a malignant 
biliary stricture treated by a Gianturco stent [201]. The survival was short: fifteen pa-
tients had died after a median survival of 11 weeks (range 0-59 weeks). Two patients 
needed reintervention in a series of 11 patients [203]. A new modification of the 
Gianturco stent with a coating and tapered ends has been developed to prevent tumor in-
growth and to reduce papillary mucosal hyperplasia at the ends of the stent [206]. No 
clinical data concerning this stent are available to date. 
Nitino/ coil spring stent 
Recently initial clinical experience with an interesting new type of stent has been 
published [207]. The stent is a coil spring self-expandable stent made of a nickel-
titanium alloy wire which has elastic and memory proporties (lnstent Inc, Israel and 
Eden Priarie, Minn, USA). This alloy stent has more radial force than stainless steel 
stents [207]. The introduction catheter is 12-F (3,5 mm) in diameter and maximum stent 
diameter is 8 mm. The authors report that the stent can be removed when reobstruction 
occurs. After a mean follow-up period of 4.5 months two cases of reobstruction 
occurred in 10 patients, tumor ingrowth and sludge were the causes. A new prototype 
with closer loops and a stronger radial force is developed. 
Ballooll-expalldable metal stenls 
Strecker stelll 
The Strecker stent (Boston Scientific, Watertown, MA, USA) is a balloon mounted stent 
made of tantalum (Fig. 2.lc). The diameter is 7 mm, the lengths varies from 4-8 cm. It 
is delivered through a 7-F sheath. The stent does not change length when released. The 
stent is radiopaque. A major advantage is its flexibility. A disadvantage, especially in 
tight strictures, is the absence of intrinsic radial force. To date the reported experience 
with the Strecker stent is limited. A percutaneous study on Strecker stents and 
Wallstents reports on partial collapse of the Strecker stent in 30% of the patients [208]. 
In two randomized series comparing plastic stents and metal stents in hilar and distal 
malignant strictures the results of the Strecker stent and the Wallstent are lumped 
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together, precluding further analysis [209,210]. A study on technical failures of the 
Wallstent and the Strecker stent reports on six (18%) technical failures of the Strecker 
stent, predominantly difficult balloon removal and partial expansion [191]. 
Paimaz stelll 
The Palmaz stent (Jobnson and Jobnson Interventional Systems, Warren, NJ, USA) is a 
balloon-expandable stent made of partially compressed diamond-shaped stainless steel 
lattices. The wall of the stent is 0.015 inches thick. The delivery system with the stent 
compressed around a deflated balloon has an outer diameter of 9-IO-F. The maximal 
diameter after dilation is 7-12 mm; length varies, depending on the diameter used, from 
2-3 em. Minimal shortening occurs during deployment. The stent is rigid, limiting its 
use in angulated segments. In these cases multiple stents should be used with sufficient 
overlap. A design modification has been made which allows articulation of the center of 
the stent at a slight angle [211]. At the articulation point only two strands of the lattice 
are present allowing angulation but, unfortunately, tumor ingrowth might be anticipated. 
A polymer-coated modification has been developed to reduce ingrowth [186]. An 
experimental study on these polymer-coated Palmaz stents in dogs has demonstrated 
good biologic tolerance, however mucosal hyperplasia did occur [186]. The Palmaz 
stent has not become popular so far, propably because of its rigidity [197]. 
2.6 Perculaneous placement of the Wallslent endoprosthesis 
In most patients in our institution Wallstent insertion is performed as a two~stage 
procedure. At the initial visit an attempt will be made to pass the stricture, except in pa-
tients with cholangitis. When this attempt is successful an 8.5-F modified multiple side 
hole Ring-Ferrucci catheter with only proximal side holes for external drainage [Cook 
Europe AIS, Bjaeverskov, Demnark] will be introduced. When the attempt to pass the 
stricture fails, an 8-F pigtail catheter [Cook EuropeNS, Bjaeverskov, Demnark] will be 
left for external drainage and the stricture will be passed at the second visit. When a 
catheter has passed the stenosis a 0.035 inch modified Amplatz extra stiff guide wire 
[Cook Europe AIS, Bjaeverskov, Demnark] is introduced through the stricture into the 
duodenum. The catheter is exchanged for a 9-F sheath [Cordis Europe NV, Roden, The 
Netherlands]. This sheath allows an easy access to the biliary system. The optimal 
length of the stent is chosen based on the cholangiographic findings and expected 
shortening of the stent. The Wallstent, loaded on the delivery catheter, is introduced 
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into the biliary system and is positioned across the stricture. Radiopaque markers on the 
delivery catheter indicate the proximal and distal end of the compressed Wallstent. 
Delivery catheters with hydromer coating between the membranes are used at our 
institution. Stent release occurs when pressure is applied to the potential space between 
the outer and inner rolling membrane of the delivery catheter together with withdrawing 
the outer shaft. The distal end of the stent is released first. At tItis moment withdrawal 
of the partly opened stent into a more favorable proximal position if desired is possible. 
With progressive release repositioning becomes more difficult, while it is impossible 
after release. After stent release correct stent position is controlled. Enough overstenting 
has to be present to allow for prolonged drainage. No balloon dilation after stent 
placement is necessary as the stent continues to expand to an adequate inner diameter. 
A safety catheter above the stent can be left in place for a few days when desired. 
2.7 Conclusion 
Endoprostheses are the palliative treatment of choice in the majority of patients with 
malignant biliary obstruction. Adequate drainage will be established in almost all 
patients. Until the late 1980s plastic endoprostheses were used which had one major 
drawback: reduced stent patency by sludge. The mechanism of stent blockage by sludge 
has been elucidated and several attempts have been made to use this information to 
design a plastic endoprosthesis with prolonged patency. Although some improvements 
occurred, reduced stent patency remained a major problem with plastic stents. A major 
breakthrough was anticipated with the introduction of metal expandable stents as these 
stents have a large inner diameter. Several metal stents are available today but the 
Wallstent endoprosthesis is the most conunonly used. The reported clirtical experience 
with all other types of metal stents in biliary stenting is limited or absent. 
Results from the literature concerning the Wallstent, together with data of our own 
series, will be analysed in the following chapters to determine the place of the Wallstent 
in current percutaneous stenting. Our results are based on a non-comparative study 
design. Although the drawbacks of such a study design were recognized it was found 
appropriate for several reasons. The initial results with the Wallstent demonstrated a 
much easier introduction which facilitated the procedure for patient and radiologist. The 
majority of the patients had a previous failed endoscopic attempt, therefore to subject 
these patients to a second procedure which would be more painful than necessary was 
not found appropriate. The endoscopic failures were partIy caused by unsuccessful 
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conventional stent introduction. The use of the during introduction smaller Wallstent 
seemed for this reason advantageous. Our results described in Chapters 3-6 were based 
on experience in a growing study population. Each three months until death a 
questionnaire was send to the patient's physician concerning the occurrence of jaundice, 
fever, or other complications. In case of possible complications further information was 
obtained from the doctor and from the hospital to which the patient was referred. 
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3.1 Abstract 
INITIAL PERCUTANEOUS EXPERIENCE 
WITH THE W ALLSTENT ENDOPROSTHESIS 
IN MALIGNANT BILIARY OBSTRUCTION 
A total of 83 self-expandable metallic stents were placed percutaneously in 69 patients 
for palliation of malignant biliary obstruction to achieve palliation. Stent diameter was 
1 cm; lenght, 3.5-10.5 cm. Of the 41 patients with a common bile duct stenosis 27 died 
0.2-12 months (median, 3.2 months) after stent insertion. Two patients developed 
recurrent jaundice and cholangitis after 6 and 12 months, respectively. One patient 
underwent reintervention. Fourteen patients were alive without jaundice 1-8 months 
(median, 6.3 months) after stent placement. 
Of the 28 patients with hilar lesions, 13 died 0.7-7.6 months (median 4.3 months) after 
stent placement. Fifteen were alive 1-15.5 months (median, 8.1 months) afterward. 
Recurrent jaundice and cholangitis were seen in eight patients of the 28 patients after 
1-6 months (median, 3.6 months). The cause of malfunction of the stent(s) was tumor 
ingrowth in onc patient, tumor overgrowth at the proximal end in five patients and 
overgrowth at the distal end in two patients. Reintervention was performed in five 
patients (18%). Stent related complications were seen in four patients. 
3.2 Introduction 
In patients with inoperable malignant biliary obstruction in whom endoscopic drainage 
of the bile ducts fails, percutaneous transhepatic biliary drainage (PTBD) is the method 
of choice for palliative treatment [1,2]. Because these patients have a very short life 
expectancy the procedure should be safe, effective, and performed only once. There is 
little question that internal drainage by means of endoprostheses is the ideal way to treat 
these patients. There are, however, several problems with the currently available 
endoprostheses, and blockage by sludge or tumor is the most frequent. This occurs 
several weeks to more than one year after stent placement. with a mean of five months 
Published as: JS Lameris, J Stoker, HOT Nijs, HM Zonderland, OT Terpstra, M van B1ankenstein, HE 
SchOlte. Malignant biliary obstruction: percutaneous use of self-expandable stents. Radiology 1991; 179: 
703-707. 
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in common bile duct (CBD) obstructions and three months in obstructiol15 in the hilar 
region, when IO-F polyethylene endoprostheses are used [3]. 
Blockage of the endoprosthesis is influenced by several factors, one of which is 
diameter [4]. The larger the diameter of the endoprosthesis, the longer it will stay 
patent. The use of self-expandable stents combines the advantages of a small delivery 
catheter (7-F) and a large stent diameter (lcm). 
In this article the long-term results of percutaneous placement of self-expandable stents 
in patients with malignant biliary obstruction are reported. 
3,3 Patients and Methods. 
From April 1989 through September 1990, 83 self-expandable stents (Wallstent; 
Medinvent, Lausanne, Switzerland) were implanted via a percutaneous transhepatic 
route in 69 patients (30 men and 39 women) with inoperable malignant biliary 
obstruction. The mean age was 67 years (range, 36-89 years). Pancreatic carcinoma was 
the cause of jaundice in 32 patients, choiangiocarcinoma in 16 patients, 
gallbladdercarcinoma in seven patients, extrahepatic metastases of various malignancies 
in 10 patients and intrahepatic metastases in the remaining four patients. The diagnoses 
were proved with either cytologic or histologic examination in 55 of 69 patients (80%). 
For 28 patients (41 %) the percutaneous drainage was the second biliary intervention, 
after either endoscopically performed drainage or after bilioenteric bypass surgery. In 
all others, endoscopic drainage was not possible for technical Of anatomic reasons. In 
41 patients the obstruction was in the CBD. Hilar obstruction was present in 28 
patients. Of these 28 patients, five had a Bismuth type I lesion (stenosis in the common 
hepatic duct); nine, a type II lesion (involvement of both hepatic ducts); 11, a type III 
lesion (involvement of both hepatic ducts, including segmental ducts in one lobe); and 
three, a type IV lesion (extel15ion to segmental ducts in both lobes) [5]. 
All PTBD procedures were performed under sonographic and fluoroscopic gnidance. 
The stents were placed 5-7 days after the initial drainage procedure. The technique of 
stent placement has been described in detail [6]. In patients with hilar obstruction who 
needed two stents (one in the right and one in the left biliary duct), the delivery 
catheters were first placed through the stenoses, and the stents were released one after 
another. Patients with three stenoses in the hilar region needed four stents to achieve 
complete drainage. In these patients, we first placed a short stent in the distal part of 
the CBD. Two stents were then placed in such a way that their distal parts ended in the 
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already inserted stent. Finally, one long stent was released from the delivery catheter 
that was already positioned through the third stenosis. 
The length of the stents varied from 6.8 to 8.5 cm in patients with CBD obstruction and 
from 3.5 to 10.5 cm in hilar obstructions. All stents had a diameter of 1 cm. Balloon 
dilation of the stenosis prior to stent insertion was perfonned only in the first five 
patients. Plain abdominal radiography to evaluate the position and the degree of 
expansion of the stents was performed 1-14 days after placement. 
The effects on jaundice and the post-procedural and late complications were recorded in 
all cases. 
3.4 Results 
The survival rates of the patients and the data on stent malfunctioning are listed in Table 
3.1. 
Table 3.1 Sun'ival after Stellt Placement, Number of Recurrences of Jaundice and Cholangitis, 
Causes of Stellt Malfullclionillg, and Number of Reinterventlons in 41 Patients with 
CBn Obstruction and 28 Patients with Hilar Obstruction 
Finding or Procedure 
Median survival after stent 
placement in months * 
Recurrent jaundice with cholangitis 
Tumor ingrowth 
No established cause 
Tumor overgrowth 
Reintervention 
* Numbers in parentheses are ranges 
COIIIIIIOII bile duct obstructioll 
eBD Obstruction 
(n ~ 41) 
Died 
(n ~ 27) 
3.2 
(0.2 - (2) 
2 
I 
I 
o 
I 
Alive 
(n ~ (4) 
6.3 
(I - 8) 
o 
o 
o 
o 
o 
Hilar Obstruction 
(n ~ 28) 
Died 
(n ~ 13) 
4.3 
(0.7 - 7.6) 
6 
o 
o 
6 
3 
Alive 
(n ~ 15) 
8.1 
(I - 15.5) 
2 
I 
o 
I 
2 
Six patients (14%) died within one month after stent placement. One died after massive 
pulmonary embolism, two died of upper gastrointestinal tract bleeding, and two died of 
disseminated malignancy. Pancreatitis was the cause of death in the other patient, an 86-
year old patient with pancreatic carcinoma. Endoscopic retrograde cholangio-
pancreatography had already disclosed a pseudocyst in the tail of the pancreas. An 
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endoscopic attempt at drainage failed, and the patient developed fever. After successful 
percutaneous drainage and subsequent stent insertion, the plasma bilirubin level dropped 
in one week from 506 to 170 I'mol/L (normal range, 4-14 I'moIlL), but sepsis persisted 
and the patient died. Autopsy disclosed severe pancreatitis of the tail of the pancreas. 
All patients had a decrease in serum bilimbin levels. Of the 27 patients who died, five 
had persistent high bilirubin levels or developed recurrent jaundice shortly before death. 
One of these five had clinical signs of cholangitis and dilated bile ducts at sonography 
12 months after stent insertion. No definite cause was established, but ingrowth might 
have been the cause. The general physical condition of the patient at that stage 
prevented further invasive treatment. One patient underwent reintervention 6 months 
after stent placement. A catheter with multiple side holes was passed through the stent, 
which had become occluded by tumor ingrowth. The patient died without jaundice 3.5 
months later. At this writing, no recurrent jaundice has developed in the 14 patients 
who are still alive. 
Hi/or obstruction 
One patient (4%) died with signs of an acute abdomen within one month. Of the 15 
patients who were still alive at the end of tlus study three survived longer than one 
year: two with the expandable stents functiorling well and one with a catheter bypassing 
a blocked stent. 
Complete drainage was achieved in all five patients with type I and in five patients with 
a type II lesions. In three of these patients, the distal ends of the stents were positioned 
in a suprapapillary location. Drainage was complete in only two of 14 patients with type 
III or IV lesions. Of the 16 patients with incomplete drainage, 13 had one stent and 
three had more than one stent. The stent position was suprapapillary in eight and 
transpapillary in six patients. 
Bilirubin levels returned to normal in all patients with type I or II lesions. In five 
patients with type III or IV lesions, bilirubin levels remained above 50 I'mollL, 
although the drainage had a satisfactory effect on pruritus. Recurrence or worserling of 
the jaundice was seen in eight patients (29%) 1-6 months (median, 3.6 months) after 
stent placement. All these patients had signs of cholangitis. The cause of recurrent 
jaundice was tumor overgrowth at the proximal end of the stent(s) in five patients, 
tumor overgrowth at the distal end in two patients and tumor ingrowth in one patient. 
Five patients underwent percutaneous reintervention: two undenvent external catheter 
drainage, one underwent internal catheter drainage and in two patients with distal tumor 
overgrowth the stents were extended into the duodenum. Two of these patients were still 
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alive after 14 and 12 months. Three patients with stent blockage died without 
undergoing further interventions. 
Complications 
Septicaemia after the initial PTBD occurred in eigth patients, all of whom had 
preexisting cholangitis. Balloon dilation of a stenosis caused by a pancreatic carcinoma 
in one case resulted in bleeding for which the patient required blood tranfusions. Stent 
insertion itself never caused complications. In two patients, bleeding from the 
transhepatic tract was controlled by leaving the drainage catheter in place for another 
two weeks after stent placement. 
Late complications other than recurrent jaundice occurred in five patients. Two patients 
with hilar obstruction developed acute cholecystitis; one of these patients underwent 
cholecystectomy, and the other percutaneous gallbladder drainage. 
Duodenal ulceration caused by constant pressure of the stent against the opposite 
mucosa was seen twice, once after placement of one stent and once after placement of 
two stents through the papilla into the duodenum. Both patients had upper abdominal 
pain and mild intestinal blood loss. A lethal complication occurred in a patient with 
cholangiocarcinoma, in whom two stents were placed through the papilla after internal 
irradiation with Iridium-l92 wires. He presented with acute abdominal pain after 21 
days and died despite acute laparotomy. At autopsy it was found that only one stent had 
a transpapillary position. The malpositioned stent had perforated the tumorous wall of 
the CBD. 
3.5 Discussion 
Recurrent jaundice or cholangitis due to clogging of endoprostheses is a major 
complication in the palliative treatment of malignant biliary obstruction. Few long-term 
follow-up studies of stent patency have been published, and the frequency of blockage 
of percutaneously placed endoprostheses varies greatly, from 6% to 23% [7,8]. The 
reintervention rate after endoscopic placement of endoprostheses in a large series of 969 
patients with malignant biliary obstruction was reported to be 35 % [9]. 
Besides the diameter of the endoprosthesis, the site of the stenosis seems to be an 
important determinant. In a series of 49 patients with hilar cholangiocarcinoma who 
received percutaneous treatment 45% of the patients needed a reintervention for blocked 
endoprostheses [10]. 
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In our study, one of the patients with CBD obstructions (2 %) and five of the patients 
with hilar lesions (18%) underwent reinterventions. These numbers compare favorably 
Figure 3.1 (a) Cholangiogram of an 89-year old patient with carcinoma of the gallbladder. 
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(b) Cholangiogram obtained immediately after sten! insertion. (e) The patient remained well 
for four months and then developed cholangitis. Cholangiogram shows tumor overgrowth 
on the left side (arrow), (d) Because of the angulation at the junction of the stent and the 
left hepatic duct, the slen! could only be entered with a small catheter through the mesh of 
the stent. Only external drainage was possible. The patient died six weeks later. 
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with the previously mentioned data from the literature. A main cause of blockage is the 
presence of biliary sludge in the lumen of the stent. The larger diameter of the self-
expandable stent and the small surface area of the stainless steel wires offers a less 
chance of sludge formation. Another cause of malfunction, such as migration of the 
endoprosthesis, is highly unlikely when expandable stents are used, because the wires 
are fixed to the wall by the expansive force. The mesh of the self-expandable stent does 
not prevent tumor ingrowth. However, with the large diameter used (1 cm), stent 
blockage due to tumor ingrowth occurs late. We did not observe tltis blockage within 
six months after stent insertion in our patients. 
The most important cause of recurrent jaundice and cholangitis after stent placement in 
hilar lesions is tumor extending beyond the length of the stent (seven of eight patients). 
Therefore, as a general rule, these stents should extend well proximal and distal to the 
obstructing lesion. However, the characteristic spread of many hilar malignancies 
eventually overgrows any stent at its proximal end and invariably occludes segmental 
ducts. In our study, this phenomenon was the most frequent type of overgrowth in 
patients with hilar lesions (five patients). Depending on the general condition of the 
patient at that stage, attempts can be made to correct this situation. An external catheter 
drainage to treat cholangitis is often the best treatment possible in these cases 
(Fig. 3.1). 
Although the open mesh of the stent can be considered as a disadvantage as far as tumor 
ingrowth is concerned, this small mesh seems to garantee drainage of secondary radicles 
Figure 3.2 Cholangiogram of a patient with 
hilar obstruction due to metastasis 
from colorectal cancer. Two short 
stents were placed in this type IV 
lesion. Bile ducls (arrow) entering 
the edge of the mesh on the right 
side can be seen. Note the 
suprapapillary position of the distal 
parts of the stent. The patient was 
alive and without jaundice four 
months after stent insertion. 
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within the intrahepatic system that end up on the edge of the stent. Thus, these stents 
work better than conventional stents, which all have relatively few side holes. This is 
especially important in draining type III and IV hilar lesions (Fig. 3.2). 
Since endoscopic exchange of these metallic stents is not possible, a suprapapillary 
positioning of the stent in hilar lesions should be considered to preserve papillary 
function and prevent ascending cholangitis. In a well drained biliary system, infected 
bile will not cause septic complications. However, in patients with Type III or IV hilar 
lesions, complete drainage of all ducts often cannot be achieved. A drawback of this 
approach is that tumor overgrowth at the distal end of the stent can occur. This occured 
in two of our patients, both of whom had carcinoma of the gallbladder, and in both 
cases the stents were extented into the duodenum in a second percutaneous intervention 
(Fig. 3.3). 
Figul'e 3.3 (a) Cholangiogram of a patient with gallbladder carcinoma and recurrent jaundice two 
months after sten! pIacement. Cholangiogram was obtained after drainage of the left lobe 
hepatic bile ducls and shows blockage at the distal end of the slenls. After drainage of the 
right lobe hepatic bile dUCIS, both stcnts and the stenosis distal to the stents were passed. 
Another two stents were then placed. (b) Abdominal radiograph obtained after extension of 
both slenls into the duodenum. The right-sided catheter was removed after it became clear 
that the stents were functioning well. 
A disadvantage of the self-expandable stent is the sharp wires on both ends. These wires 
were believed to have caused duodenal ulcerations in two patients, and a lethal CBD 
perforation in one patient. To what extent the intraluminal lr-192 irradiation contributed 
to this latter serious complication is not clear. Radiation therapy followed by placement 
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of conventional endoprostheses has, to our knowledge, never resulted in perforation, 
nor was this complication reported to result from the use of expandable stents. 
It is important to realize that self-expandable stents shorten by 40% while they are 
expanding. This so-called understenting was the cause of recunent jaundice in seven out 
of 19 cases in a previous report [6]. With lengths up to 10.5 cm this problem can be 
avoided. Despite its expansive force, the self-expandable stent is subjected to another 
force that will straighten it. Eventually the stent may not retain the form of the bile 
duct. The proximal end of the stent will become occluded by the wall of the bile duct 
(Fig. 3.4). Drainage will then be possible only through the open mesh of the stent. 
A B c D 
Figure 3.4 (a and b) Acute angulation at junction of the stent and the normal duct can occur when 
short stents are used. (c and d) This problem can be prevented by using long stenls. 
Furthermore, the chance of damage to the bile duct epithelium by the sharp, wires will 
increase. In a distal stenosis, this can be prevented by using a stent of adequate length 
and "overstenting" the lesion at the proximal site (Fig. 3.5). However, in hilar lesions 
angling of the stent axis, especially in the left hepatic duct, is difficult to prevent, 
because "overstenting" can be done only to a limited degree (Fig. 3.1). 
The use of self-expandable stents increase the cost of biliary drainage. Balloon dilation 
of the stenosis before and after insertion of the stent, as recommended, increases the 
costs even more. When we observed the natural tendency of these stents to continue 
expanding for a few days, we abandoned balloon dilation. Theoretically, the selfexpan-
dable stent can be placed in one session, thereby reducing the costs of hospitalisation. 
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Figure 3,5 Images from a patient with inoperable pancreatic carcinoma and a blocked endoproslhesis 
placed by means of endoscopy. (a) The stenosis in the distal part of the CBO is 
noverstented" from the hilar region to the duodenum. (b) Plain radiograph obtained five 
days latcr shows that the sten! has almost fully expanded. The shortened stent retains the 
form of the CBD. The blocked endoproslhesis, which was pushed into the duodenum, is 
now seen in the right lower quadrant of the abdomen. 
In the majority of our patients, the presence of cholangitis or complex biliary strictures 
was the reason that stent placement was performed as a two stage procedure. 
In conclusion, placement of the self-expandable stent in patients with malignant CBn 
and hilar obstmction who are referred for percutaneous drainage is safe and effective. 
The rate of reinterventions is low and compares favorably with rates in previous studies 
with conventional endoprotheses. 
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4 THE PERCUTANEOUS USE OF THE WALLSTENT ENDOPROSTHESIS IN MALIGNANT HILAR BILIARY OBSTRUCTION 
4.1 Abstract 
Forty-five patients with malignant hilar obstruction were treated with a total of 68 
percutaneously inserted self-expandable endoprostheses (Wallstents) for palliative biliary 
drainage. The stent diameter was 1 cm; the length was 3.5-10.5 cm. Early 
complications occurred in seven patients (16%), including cholangitis in four patients 
(9%). The 30-day mortality rate was 9%, with two procedure-related deaths (4%). 
Of the 45 patients, 29 died between 10 and 550 days (median, 126 days) after stent 
insertion. Reobstruction occurred in 13 of these patients after 26 to 184 days (median, 
105 days). Sixteen patients were alive 44 to 737 days (median, 305 days) after stent 
insertion. Reobstruction occurred in four patients after 142 to 279 days (median, 246 
days). The cause of reobstruction was proximal overgrowth in seven patients; distal 
overgrowth in four patients; and tumor ingrowth and proximal overgrowth, tumor 
ingrowth, hemobilia, and angling of the stent in one patient each. The cause of 
reobstruction was not established in two patients. Reintervention was performed in 14 
patients (31 %). 
Because reobstruction of Wallstent endoprostheses is primarily not stent-related but 
rather is caused by tumor progression, and because insertion and reintervention is 
easier, we consider the use of the Wallstent in malignant hilar biliary obstruction 
advantageous in comparison with plastic stents. 
4.2 Introduction 
Malignant biliary obstruction of the hilus of the liver is caused by a heterogeneous 
group of tumors for which curative surgery is possible in a limited number of patients. 
Percutaneously inserted endoprostheses are one of the recognized options of palliative 
biliary drainage in the remaining patients [1,2]. The ideal endoprothesis should be easily 
insertable with no complications Of only a limited number of complications, should 
Published as: J Stoker, JS Lameris, M van B1ankenslein. Percutaneous metallic self-expandable 
endoprostheses in malignant hilar biliary obstruction. Ga<>troinlest Endosc 1993; 39: 4349. 
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remain in place, and should stay open until death. The currently available plastic 
endoprostheses do not satisfy these requirements primarily because of stent blockage [3-
5]. Several new designs of plastic endoprostheses have been developed in an attempt to 
overcome these difficulties, but several problems, such as stent patency, remain [3]. 
The introduction of self-expandable biliary endoprostheses is the next attempt to come 
closer to the ideal endoprothesis. It combines the advantages of a small delivery 
catheter, large stent diameter and fixation of the stent against the wall. This paper 
reports our two-year experience with percutaneously inserted metallic self-expandable 
endoprostheses in malignant hilar lesions. 
4.3 Patients and Methods 
From April 1989 through April 1991, 47 patients with inoperable malignant hilar biliary 
obstruction were treated by percutaneous drainage. Routine management at our 
institution is initial catheter drainage, with Wallstent insertion after several days. This 
provides the opportunity to evaluate the effect of the drainage. In 45 patients a total of 
68 metallic self-expandable endoprostheses (Wallstent, Medinvent, Lausanne, 
Switzerland) were inserted. Two patients not included in this study remained on catheter 
drainage because of persistent cholangitis after the initial drainage procedure. 
Table 4.1 Diagnosis and Type of Hilar Stricture in 45 Patients 
with Hilar Strictures 
Type of Obstruction * 
Diagnosis II IJJ IV 
Choiangiocarcinoma (n ~ 22) 1 3 12 6 
Gallbladder carcinoma (n ~ 9) 2 2 5 0 
Liver metastasis (n ~ 7) 0 1 3 3 
PeriportaIlymphoma (n ~ 3) 1 2 0 0 
Olher causes # (n ~ 4) 2 1 0 I 
Total 6 9 20 10 
* Type of hilar stricture according to Bismuth et aI. 6 
# Other causes include the following: one infiltralinggastric carcinoma. 
onc local recurrence of a pancreas carcinoma after a Whipple procedure, 
one local recurrence after resection of a renal cell tumor, and one 
hepatocellular carcinoma. 
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The study population comprised 23 men and 22 women with a mean age of 65 years 
(range, 36-89 years). Diagnosis and type of hilar stricture, according to Bismuth, 
Castaing, and Traynor are listed in Table 4.1 [6]. A Bismuth type I lesion is a stenosis 
in the common hepatic duct, a type II lesion has involvement of both hepatic ducts, a 
type III lesion has extension to segmental ducts in one lobe, and a type IV lesion has 
extension of tumor to segmental ducts in both lobes. Histologic or cytologic proof of the 
diagnosis was obtained in 34 of the 45 patients (76%), whereas in the remaining 11 
patients the diagnosis was based on clinical and radiologic rmdings; follow-up left no 
doubt concerning the diagnosis. 
In 32 patients, endoscopic placement of an endoprosthesis was attempted previously, but 
it failed to achieve initial drainage in 22 patients or failed to replace a previous plastic 
endoscopic stent in 10 patients. One patient had a previous percutaneous plastic stent. 
Twelve patients had previous biliary surgery, which included the following: three 
patients had a hepaticojejunostomy, one patient had a Whipple procedure, one patient 
had a peroperative stent, six patients had a total or partial cholecystectomy, and one 
patient had a cholecystojejunostomy. Radiotherapy was performed in 19 patients (15 
cholangiocarcinoma, two gallbladder carcinoma, and two metastases). Thirteen patients 
received external and intraluminal radiotherapy, four received patients external 
radiotherapy and two patients received intraluminal radiotherapy. In two patients this 
radiotherapy was given several months to one year before stent insertion. Twelve 
patients had cholangitis before the percutaneous procedure. The blood bilirubin 
concentration before the procedure was 9 - 555 I'mollL (mean, 230 I'mollL; normal 
range, 4 to 14 I'moIlL). 
All percutaneous transhepatic biliary drainage procedures were performed using 
sonographic and fluoroscopic guidance. Broad-spectrum antibiotics were given for 12 
hours before and after each procedure. The stents were placed five to seven days after 
the initial drainage procedure when cholangitis, when present, had disappeared. One 
patient with cholangitis in this series had placement of the Wallstent at the initial visit 
because of percutaneously drained ascites. This patient had persistent cholangitis after 
the procedure and developed an abscess in the right liver lobe. In patients who needed 
two stents (one in the right and one in the left biliary duct), the delivery catheters were 
first placed through the stenoses, and the stents were released one after another. Patients 
with three stenoses needed four stents to achieve complete drainage. In these patients a 
short stent was first placed in the distal part of the common bile duct. Two stents were 
then placed in such a way that their distal parts ended in the already inserted stent. 
Finally, one long stent was released from the delivery catheter that was already 
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positioned through the third stenosis. 
All stents had a diameter of 1 cm, the length varied from 3.5 to 10.5 cm. No balloon 
dilation was performed before stent insertion. Prepapillary position of the stent was 
especially considered in patients with incomplete drainage to prevent direct 
communication between the gut and the biliary system, which might lead to ascending 
cholangitis. Plain abdominal radiography to evaluate the position and degree of 
expansion of the stents was performed 1 to 14 days after insertion. The effect on 
jaundice, the complications, and follow-up were recorded for all patients. Early 
complications were defined as complications occurring within 30 days after stent 
placement. Cholangitis was defined as a temperature greater than 38° C, in the absence 
of any other obvious explanation. The blood bilirubin concentration was recorded 
approximately one month after stent placement. The patency period of the stent was 
taken as the interval between the insertion of the prosthesis and the time of biliary 
obstruction, as defined by clinical symptoms, ultrasound, and cholangiographic findings. 
4.4 Results 
Wallstent insertion was successful and uneventful in all patients. Preexisting cholangitis 
disappeared in all patients except one. 
Complete drainage was established in all six patients with a type I hilar obstruction, in 
five patients with a type II lesion, and in six patients with a type III lesion (Fig. 4.1). 
The other 28 patients had incomplete drainage (Fig. 4.2). The stent had a transpapillary 
position in 25 patients, whereas, of the 20 patients with a prepapillary positioned stent, 
only eight had an intact papilla of Vater. Adequate stent expansion was seen in all 
patients. The stents expanded in general to an upper limit of 8 mm in the hepatic ducts, 
and full expansion occurred in the common bile duct. Jaundice decreased in all patients, 
although one patient with sclerosing cholangitis, complicated by cholangiocarcinoma, 
showed jaundice and bilirubin increase only days after initial decrease. Blood bilirubin 
analysis after stent insertion was available for 36 of the 45 patients. Bilirubin decrease 
was found in all of them, with bilirubin falling to less than twice the upper limit of 
normal in 22 patients. 
Seven patients (16%) had early complications. Early cholangitis occurred aner the 
initial drainage in four patients, all of whom had incomplete drainage. The cholangitis 
was treated successfully by antibiotics in three patients, and no sepsis occurred. The 
fourth patient, who had Wallstent placement at the initial visit, died of cholangitis and 
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Figure 4.1 Patient with colorectal metastasis to 
the hilum of the liver. Complete 
drainage was established in this 
type II hilar obstruction. (a) 
Cholangiography after external 
drainage of right and left lobe bile 
ducts. (b) Delivery catheters 
inserted through the stenosis. (c) 
Expansion of the stents after two 
days. 
sepsis caused by an abscess in the undrained right lobe. This patient had cholangitis 
before percutaneous intervention after an endoscopic attempt at stent insertion. A 
subhepatic abscess occurred in a patient after removal of the percutaneous biliary 
catheter by the ward physician before stent placement. This abscess was treated by 
percutaneous drainage. One patient with hepatocellular carcinoma had persistent 
hemobilia after the initial drainage procedure. Occlusion of the stent occurred after 26 
days and was treated by a left-sided catheter. This catheter again revealed blood stained 
bile and occluded after five days. A new catheter remained in place until death. This 
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patient also developed acute cholecystitis 11 days after Wallstent placement, which was 
drained percutaneously. He died with jaundice, but without fever, 79 days after stent 
insertion. One patient died 21 days after stent placement due to a malpositioned 
Wallstent [7). This patient had been treated with iridium-192 brachytherapy and had two 
parallel transpapillary Wallstents. At autopsy only one stent had a transpapillary 
position, and the other had perforated the tumorous common bile duct wall. 
Figure 4.2 Type III malignant hilar obstruction in a patient with coiorcclal metastasis to the liver hilus. 
Incomplete drainage was established. (a) Cholangiography after placement of internal 
drainage catheter. Arrows indicate the length of the stenosis. (b) Siell! expansion after one 
day. 
Four patients died within 30 days (9%), including two procedure-related deaths (4%), 
which have been described above. The other two patients died of disseminated 
malignancy. 
Late complications other than recurrent jaundice occurred in four patients. One patient 
developed cholecystitis five months after stent insertion and was treated by 
cholecystectomy. Another patient with cholecystitis was treated by percutaneous 
drainage. Pressure ulceration of the duodenum opposite to the Wallstent was seen 
endoscopically in a patient who presented with upper abdominal pain and mild intestinal 
blood loss 32 days after stent placement. The fourth patient, who initially had a type I 
lesion, developed an abscess in the right liver lobe, which was treated by a 
percutaneous catheter. Tllis patient died with sepsis and peritonitis. 
Sixteen patients are alive, with a median follow-up of 305 days after stent placement 
60 
Hilar strictures 
Table 4.2 Survil-'al after Stent Placement, Number of Reobstructions, Period between Stent 
Placement and Reobstruction and Number of Reinferventiolls in 45 Patients with 
Hilar Stricture Treated by Wallstents 
Finding or procedure 
Median survival after stellt placement * (days) 
Reobstruction 
Median period between stent 
placement and reobstruction * (days) 
Reintervention 
* Numbers in parentheses are ranges. 
Deceased 
(n ~ 29) 
126 (10 to 550) 
13 
105 (26 to 184) 
10 
Survived 
(n ~ 16) 
305 (44 to 737) 
4 
246 (142 to 279) 
4 
(Table 4.2). Four of the 16 patients had biliary reobstruction after a median period of 
246 days after insertion. Twenty-nine patients have died, with a median survival of 126 
days after stent insertion, which includes the four patients who died within 30 days. Five 
of them had jaundice without fever in the terminal phase. Four had incomplete drainage 
and liver metastasis, and the fifth had sclerosing cholangitis. It remains unclear whether 
stent obstruction attributed to the jaundice. One other patient with liver metastasis 
developed progressive jaundice. An ultrasonography shortly before the patient's death 
revealed no biliary obstruction. This patient had fever at death. Biliary reobstruction 
occurred after a median period of 105 days in 13 of the 29 patients who died. 
Figure 4.3 Patient with a type III cholangiocarcinoma. Complete drainage was established. 
(a) Cholangiography during stent placement. TIle stent in the left hepatic duct will retain the 
fonn of the duct. (b) Situation after six months. The stent in the left hepatic duct has an 
angulated position. The course of the left hepatic duct is indicated by the guide wire. 
61 
Chapter 4 
The cause of the biliary reobstruction was established in 15 of the 17 patients affected. 
Tumor overgrowth at the proximal end of the stent occurred in seven patients, distal 
overgrowth occurred in four patients, tumor ingrowth and proximal overgrowth occurred 
in one patient, tumor ingrowth occurred in one patient, hemobilia occurred in one 
patient, and another patient had obstruction caused by angling of the stent combined with 
sludge (Fig. 4.3). Cytologic confirmation was obtained in one patient with tumor 
ingrowth. All four patients with distal overgrowth had prepapillary stents. Two of the 
four patients had cholangiocarcinoma, one had liver metastases and, one had periportal 
lymphoma. Biliary reobstruction occurred in nine of the 17 patients with complete 
drainage, in eight of the 28 patients with incomplete drainage, in nine of the 25 patients 
with a transpapillary stent, and eight of the 20 with a prepapillary stent. Three of the 
eight patients with a prepapillary stent had an intact papilla of Vater. Table 4.3 
demonstrates biliary reobstruction in relation to the diagnosis and type of hilar stenosis. 
Table 4.3 Number of Biliary Reobstruetions in Relation to the 
Diagnosis and Type of Stricture in 45 Patients with 
Hilar Stricture Treated by Walls tents 
Type of obstruction * 
Total 
Diagnosis II 1Il IV 
Cholangiocarcinoma (11 - 22) 0 2 4 I 7 
Gallbladder carcinoma (11 ~ 9) t 0 3 0 4 
Liver metastasis (n ~ 7) 0 0 I 0 I 
Periportal Iynlphoma (11 ~ 3) I I 0 0 2 
Other causes (n ~ 4) 1 1 0 1 3 
Total 3 4 8 2 17 
• Type of hilar stricture according to Bismuth ct aL 6 
Reintervention was performed in 14 patients (31%). Eight of these patients were treated 
by catheter drainage, three patients were treated by a new Wallstent that stented the 
distal tumor overgrowth in two patients and proximal overgrowth in one patient, and left 
internal catheter drainage and segmental external catheter drainage was established in 
another patient. One patient initially treated by catheter drainage was eventually treated 
by a Wallstent and a left segmental external catheter. An endoscopic attempt to 
reestablish patency by guide wire manipulation through the stent lumen caused relief of 
symptoms in another patient. Cholangitis occurred in two patients after reintervention, 
including the patient with the endoscopic guide wire manipulation. Ten of the 14 patients 
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died 46 to 366 days (median, 96 days) after reintervention, and four patients were alive 
after 30 to 272 days (median, 99 days). Although 12 of the 14 patients initially benefited 
from the biliary reinterventioll, eight had recurrence of jaundice or fever. 
4.5 Discussion 
Jaundice recurrence after endoprosthesis insertion is a major problem in palliative biliary 
drainage. Several attempts have been made to improve the stent design. Until the late 
19808, stents differed mainly in geometric design and, to a lesser extent, in stent 
materials [3]. A larger inner diameter was recognized as an important factor for 
prolonged patency but was associated with increased risk of complications [3,8]. In 
recent years several studies have been published concerning the use of metal self-
expandable endoprostheses in the biliary tree [9-19]. Most studies were concerned with 
the Wallstent endoprostheses, as in this study [12-19]. These endoprostheses have a small 
delivery catheter (7-F), large inner diameter (1 cm), and fixation of the stent.against the 
wall. Drainage of secondMorder radicles, which end up on the edge of the stent, is 
possible through the mesh of the stent. 
Percutaneous or endoscopic insertion of plastic endoprostheses in hilar strictures has been 
successful in a large number of patients. The type of stricture is an important factor 
influencing the success rate, with an insertion success rate up to 90% or more in 
achieving incomplete drainage [20-23]. Insertion seems even more successful with the 
use of self-expandable endoprostheses [9-19]. Effective biliary drainage is accomplished 
in this way in most patients. 
Both the success rate and complication rate are influenced by the choice for complete or 
incomplete drainage. Supporters of complete drainage emphasize the risk of cholangitis 
and inadequate drainage in incomplete drainage. Others advocate incomplete drainage 
because of the expected lower risk of complications and because adequate palliation can 
be achieved by drainage of only 25% of the liver [22]. These opinions are reflected in 
the literature, with studies favoring one approach or the other [20,22-24]. Drainage is 
complete with one stent in every type I lesion, whereas complete drainage is hard to 
establish in type IV lesions. The choice between complete and incomplete drainage 
therefore concerns type II and III lesions. The progression of the malignancy will, at a 
certain moment, change each complete drainage into an incomplete drainage. 
The major problem in incomplete drainage, and most common early complication in 
biliary drainage, is cholangitis. Several studies report different rates, but occurrence in 
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approximately 10% of the patients is a common finding, and some studies report up to 
40 to 50%, depending on the complexity of the stricture and whether complete drainage 
was established [20,22-25]. Four patients (9%) in tlus study had early cholangitis, all 
with incomplete drainage. One of these patients died of cholangitis and sepsis caused by 
an abscess in an undrained right liver lobe. No early cholangitis occurred in patients with 
complete drainage. These findings, although concerning a limited number of patients, 
support the hypothesis of increased occurence of cholangitis in incomplete drainage. One 
might expect more procedure-related complications in complete drainage, but none 
occurred in this study. Initial catheter drainage is routine at our institution, with 
Wallstent insertion after several days. Tlus provides the opportunity to evaluate the effect 
of the drainage. In the only patient where this routine was not applied an abscess 
developed in the undrained right lobe. In two patients not included in this study tlus 
management prevented Wallstent insertion because adequate drainage was not 
established. The 30-day mortality rate (9%, procedure-related in 4%) and late 
complications not related to jaundice recurrence (7%) in tills study are comparable with 
recent studies on plastic or metal endoprostheses [11,12,17,20,23]. 
The most common late complication and major drawback of biliary stenting is jaundice 
recurrence by stent occlusion. It occurs in 10% to 50% of plastic endoprostheses for 
distal biliary strictures, with a mean patency of approximately five months [6,20,26-28]. 
Plastic stents perform less favorably in hilar strictures, with a mean jaundice recurrence 
in approximately three months [26]. One study observed a tendency, although not 
statistical significant, for longer patency in less advanced cholangiocarcinoma compared 
with more extensive cholangiocarcinoma [20]. 
Experience with stenting of malignant hilar strictures by self-expandable s(ents is limited 
and predominantly concerns \Vallstcnts. Comparison of studies is, as with conventional 
stenting, hampered by several factors. One of the major obstacles is that most of the 
studies have not documented the type of hilar strictures and have not related 
complications and patency to the type of stricture. Despite this lack of documentation, 
some tendencies can be identified. Jaundice recurs more frequently in hilar strictures than 
in distal strictures, as is the case with conventional stenting [13,19]. Jaundice recurrence 
has been documented in only 5% to II % of patients with distal strictures treated by 
Wallstents [14,19]. In one study, jaundice recurrence with or without sepsis was reported 
in 45% of patients with lular strictures treated by Wallstents [13]. Another study 
concerning Wallstent cndoprostheses in hilar strictures reported no jaundice recurrence, 
but this study had a short follow-up period of two months [16]. Several other studies 
[12,17,18] include patients with hilar strictures, but patency has not been grouped 
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separately for hilar strictures. One of these studies reports a jaundice recurrence of 17%, 
with stent patency of 78% after 200 days [18]. 
In our study, there was recurrence of jaundice by biliary obstruction in 17 of the 45 
patients (38%). It is not completely certain, however, whether some of the patients with 
jaundice attributed to liver metastasis should be included in this group, thereby 
increasing the occlusion rate, Tumor overgrowth was the major cause of biliary 
reohstruction in this study. Distal overgrowth occurred in four patients, all of whom had 
a prepapillary positioned stent. This can be prevented by longer initial stents. Proximal 
overgrowth is more difficult to treat. The hilar malignancies will inevitably progress, 
with stricturing of segmental ducts and second-order radicles. Tumor ingrowth through 
the mesh of the Wallstent occurs, but it has not been identified as a major cause of 
biliary obstruction in Wallstents as in our study [18,19]. Sludge and stent lnigration are 
not important causes of biliary reobstruction in metal stcnts because of their large iuner 
diameter and fixed position against the wall. 
The patency rate of \Vallstent clldoprostheses in malignant hilar strictures in tlus study is 
encouraging. The expected low incidence of reobstruction by sludge is demonstrated in 
this and other series, whereas it is identified as a major cause of reobstruction in only 
one study [13]. The major cause of reobstruction is proximal overgrowth, which is 
inherent in the diseases. This can be partly prevented by more proximal overstenting, but 
this is limited by the number and size of the affected ducts and would not prevent 
obstruction of smaller ducts, that end up on the stent because of tumor progression. 
Reobstruction is therefore primarily a sign of progressive disease, and stent-related 
causes are less common in \Vallstents compared with plastic stents. One of the specific 
characteristics of the Wallstent is the straightening force of the stent. This may lead to 
angling of the stent against the wall, which may cause reobstruction, as occurred in one 
patient in tIus series (Fig. 4.3) [19]. In our opinion one of the most important advantages 
of the Wanstent, as compared with plastic stents, is the easier reintervention because it 
can be performed without stent removal. The large inner diameter of the stent allows 
placement of another stent or catheter through the lumen. Meaningful comparison 
between complete and incomplete drainage, prepapillary or transpapillary stent position, 
and type of stricture or diagnosis with regard to stent patency is difficult in tlus study 
because of the relatively small number of patients. Comparisons are also influenced by 
the predominance of incomplete drainage and prepapillary stent position in more 
extensive strictures. No clear difference exists in the occurence of reobstruction between 
prepapillary and transpapillary stents, whereas reobstruction does occur more frequently 
with complete drainage and in low-type strictures. This may be explained by the fact that 
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survival in low~type stricture, with predominantly complete drainage, is longer. 
Rcobstruction was relatively uncommon in cholangiocarcinoma and liver metastases. 
In comparing the use of \Vallstent cndoprostheses with plastic stents, although superior 
patency rate is not proven and procedure costs arc increased with Wallstents, we 
consider the latter to be the stent of choice, because of the ease of insertion and the ease 
of reintervention [29]. 
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5 THE PERCUTANEOUS USE OF THE WALLSTENT ENDOPROSTHESIS IN MALIGNANT DISTAL BILIARY OBSTRUCTION 
5.1 Abstract 
Seventy-five patients with malignant distal biliary obstruction were treated by 
percutaneously placed self-expandable Wallstent endoprostheses for palliative drainage. 
Stent diameter was 1 cm and its length 3.5-10.5 cm. Early complications occurred in 16 
patients (21 %), they were related to the endoprosthesis in five patients (7%) and serious 
in six patients (8%). The thirty-day mortality was 15%, with 1 % procedure-related 
mortality rate. Sixty-five patients died six-365 (median 87) days after stent insertion and 
four had recurrence of obstruction after 21-341 (median 152) days. Reobstruction was 
the result of tumor ingrowth in one patient, angling of the stent in one and an 
unestablished cause in two. Ten patients were alive without obstruction 31-383 (median 
65) days after stent insertion. Percutaneous use of the Wallstent endoprosthesis allows 
easy insertion; reobstruction is rare. 
5.2 Introduction 
Inoperable malignant non-hilar biliary obstruction may be palliated by endoscopic or 
percutaneous insertion of an endoprosthesis. Currently available plastic prostheses 
frequently block with sludge and, less commonly, migrate. Changes in stent design to 
reduce blockage rates have met with ordy limited success [1]. 
Self-expandable metallic endoprostheses have recently been introduced [2]. These have 
a large inner diameter after release; this is an important factor in prolonging stent 
patency [3]. The expansile force of the stent against the bile duct wall prevents 
migration. The Wallstent endoprosthesis (Wallstent, Schneider, Btilach, Switzerland) 
used in the present study is composed of a stairdess steel braided self-expandable mesh 
and is loaded in compressed form on a small (7- F) delivery catheter, to be released by 
progressive withdrawal of the enclosing membrane. 
Experience with the Wallstent endoprosthesis and its role in the stenting of malignant 
distal biliary strictures are described. 
This chapter was published as: J Stoker, IS Lameris, J Ieekel. Percutaneously placed Wallstcnt endo-
prosthesis in patients with malignant distal biliary obstruction. Br J Surg 1993; 80: 1185-1187. 
69 
Chapter 5 
5.3 Patients and methods 
Between 1989 and 1991, 75 patients with inoperable malignant biliary obstruction distal 
to the liver hilum were treated by percutaneous insertion of a Wallstent endoprosthesis. 
There were 36 men and 39 women with a median age of 72 (range, 36-91) years. Fifty-
three patients had pancreatic carcinoma, four cholangiocarcinoma, 12 periportal 
metastasis and six obstruction due to miscellaneous malignant causes, Histological or 
cytological confirmation of the diagnosis was obtained in 47 patients (63%). In the 
remaining 28 patients the diagnosis was based on clinical and radiological findings, and 
follow-up gave no doubt concerning the diagnosis. The majority of patients had 
treatment before percutaneous stenting (Table 5.1). Eighteen patients had cholangitis 
before the percutaneous procedure. The serum bilirubin concentration was measured 
before stent placement in 67 patients and the median value was 185 I'mollL (range, 29-
5661'mo1lL; normal range, 4-14 I'moIlL). 
Table 5.1 Previous Therapy in 7S Patients Treated by 
Percutaneous Wallstent Endoproslhcsis 
Insertion 
Failed endoscopic auempt 
Failed endoscopic replacement 
Previous percutaneous endoproslhesis 
Palliative biliary bypass 
Whipple's procedure 
Cholecystectomy 
Gastroenterostomy 
External radiothcraphy 
50 
12 
1 
5 
1 
1 
5 
5 
All percutaneous transhepatic biliary drainage procedures were performed under 
ultrasonographic and fluoroscopic guidance. Broad-spectrum antibiotics were used 
during the 12 h before and after each procedure. All stents had a diameter of 1 cm; the 
length varied from 3.5 to 10.5 cm. Balloon dilation was performed before stent 
insertion in the first five patients. This was subsequently abandoned as the prostheses 
continued to expand for a few days after placement. Plain abdominal radiography 
confirmed the position and degree of expansion of the stents 1-14 days after insertion. 
The effect on jaundice, complications and follow-up were recorded for all patients. 
Early complications were those occurring within 30 days of stent placement. Cholangitis 
lVas defined as fever above 38°C in the absence of other explanations. Bleeding was 
assumed after a haemoglobin reduction of 0.5 mmol Fe2+/L or more in the absence of 
other explanations. The serum bilirubin concentration lVas recorded approximately one 
70 
Distal Strictures 
month after stent placement. The patency period of the prosthesis was taken as the 
interval between its insertion and the occurrence of biliary obstruction, as deflned by 
clinical symptoms, and ultrasonographic and cholangiographic findings. 
5.4 Results 
Wallstent insertion (Fig 5.1) was successful and uneventful in all patients. Stent 
expansion to more than 80 % of the maximal diameter was seen in all cases. Preexisting 
cholangitis resolved in all but two patients. Serum bilirubin concentration after stent 
insertion was measured in 47 patients, and showed decrease in ail, with a level 
measured of less than twice the upper limit of nonnal in 21 patients after 30 days. 
Figure 5.1 (0) Cholangiogram after insertion of a Wallstent endoprosthesis in a patient with pancreatic 
carcinoma. (b) PlaiD abdominal radiograph four days after insertion demonstrates further 
expansion of the stent. 
Early complications occurred in 16 patients (21 %); they were related to the stent in five 
(7%) and serious in six (8%) (septicaemia, four; pleural empyema, one; reobstruction, 
one). Seven patients had cholangitis, including four patients with preexisting cholangitis. 
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Four of these seven had septicaemia but all recovered following antibiotic 
administration. In four patients bleeding of the transhepatic tract was noticed during 
catheter manipulation, and controlled by leaving the drainage catheter in place for two 
weeks after stent insertion. Bleeding, bile leakage along the catheter and catheter 
dislocation occurred in one patient each and were treated conservatively. A debilitated 
patient with a transpleural catheter developed a pleural empyema; no therapy was 
performed as the patient was terminally ill. Reobstruction due to angling of the stent 
occurred in one patient 21 days after insertion. A patient with a pancreatic carcinoma 
had an aggrevation of a preexisting pancreatitis after an endoscopic attempt at drainage. 
Septicaemia persisted after successful percutaneous biliary drainage. The septicaemia 
was attributed to the pancreatitis and not to the percutaneous procedure. This was 
confirmed at autopsy. 
The thirty-day mortality was 15 %, with a 1 % procedure related mortality rate. 
Late complications, other than recurrent jaundice, occurred in two patients. One patient 
developed a pressure ulcer of the duodenum opposite the stent and another had melaena 
at 45 days that was attributed to the prosthesis as no other cause was found. 
Gastroenterostomy was necessary in two patients. 
Recurrent jaundice due to stent obstruction occurred in four patients after 21, 127, 176 
and 341 days. Tumor ingrowth caused reobstruction in one patient and angulation of the 
stent caused recurrent jaundice in another. The first patient was treated by catheter 
drainage, the second by proximal lengthening of the stent. There was clinical suspicion 
of reobstruction in two terminally ill patients but no definitive cause was established. 
Ten patients remain alive after a median follow-up of 65 (range, 31-383) days, with no 
recurrence of obstruction so far. The other 65 patients died, with a median survival of 
87 (range, 6-365) days after stent placement. The four patients with reobstruction 
occurred in this group. 
5.5 Discussion 
Curative surgery is often not feasible in patients with malignant distal biliary 
obstruction. Palliative biliary bypass may be performed, but non-surgical drainage by 
stent insertion has proved an important alternative and provides better results than 
biliary surgery in many institutions [4-7]. Efforts have been made to design an 
endoprosthesis that is easy to insert and remains patent until death. The major 
disadvantage of the plastic stents currently available is reobstruction by sludge. Increase 
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of stent diameter might prolong patency but is limited by several factors, such as more 
difficult manipulation and the possibility of more complications. The design of the self-
expandable Wallstent endoprosthesis, with its small delivery catheter, large inner 
diameter, relatively small surface area and fixation against the wall, seems advantageous 
in theory, but trial results are required. 
Before comparing the present study with other (especially endoscopic) studies on biliary 
stenting, the differences in study popUlations should be considered. The majority of the 
patients in the present study had one or more failed endoscopic attempts. This increases 
the risk of early complications, especially cholangitis, and this patient group is probably 
more difficult to treat, as one method has already failed. 
Early complications in this series, predominantly cholangitis, occurred in 21 % of 
patients, a rate comparable to plastic stents [7-11]. The majority of the early 
complications were caused by the initial catheter drainage and most of these patients had 
a previous failed endoscopic attempt, thus increasing the risk of cholangitis. Most 
complications were minor complications and other studies concerning the Wallstent 
endoprosthesis have reported a wide range of early complications [2,12-14]. 
Reobstruction of plastic stents in malignant distal stricture occurs in approximately 20-
40% of cases after 3-5 months [4,5,7,10,11,15] and therefore the rate (5%) associated 
with the Wallstent in this present series compares favourably. Blockage by sludge, the 
major problem in biliary stenting, has become a rare cause of reobstruction [2,12-14,16-
19]. TUmor overgrowth seldom causes reobstruction when stents of an adequate length 
are used. Tumour ingrowth through the mesh of the stent occurs but, since the inner 
stent diameter is large and survival is short, stent obstruction will remain a relatively 
rare event. 
Besides its expanding force the Wallstent prosthesis has a straightening force; this may 
result in the stent not retaining the form of the bile duct, with subsequent occlusion of 
the proximal end of the stent by the bile duct wall, as occurred in one patient in the 
present study. This problem can be treated by proximal lengthening of the stent and 
prevented by using longer stents initially. Reintervention is more easily performed than 
with plastic prostheses, because another stent or catheter can be placed through the 
lumen, without the need for stent removal. 
The use of the Wallstent endoprosthesis increases the cost of the procedure, and this 
must be weighed against the reduction in the rate of reobstruction and consequent 
decrease in the costs of reintervention and rehospitalization [20]. Percutaneous insertion 
of the Wallstent endoprosthesis to establish defmitive biliary drainage without 
recurrence of jaundice by reobstruction was accomplished in most patients in this study. 
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6 COMPLICATIONS OF THE PERCUTANEOUSLY INSERTED WALLSTENT ENDOPROSTHESIS IN MALIGNANT BILIARY OBSTRUCTION 
6.1 Abstract 
Purpose: Complications were assessed during and after percutaneous Wallstent 
endoprosthesis insertion in patients with inoperable malignant biliary obstruction. 
Patients and methods: Two hundred seven Wallstents were inserted in 176 patients: 74 
had hilar strictures and 102 had distal strictures. Median survival after stent placement 
was 95 days. 
Results: Early complications occurred in 12 patients (7%), predominantly cholangitis 
and reobstruction. Thirty-day mortality was 12 %; 2% of deaths (three patients) were 
procedure related. Late complications, predominantly reobstruction, occurred in 36 
patients (20%). Obstruction recurred in 33 patients (19%) after a median period of 135 
days; 27 had a hilar stricture. Tumor overgrowth was the major cause of reobstruction 
(n= 19), especially proximal overgrowth. Tumor ingrowth caused reobstruction in three 
patients. Other causes were rare. No reobstruction due to sludge occurred. 
Reintervention was performed in 25 patients. Nineteen of the 25 patients benefited from 
repeated intervention. 
Conclusion: The use of the Wallstent is preferable to use of a plastic stent, as the major 
complication - reobstruction - is not stent related predominantly but is caused by tumor 
progression. 
6.2 Introduction 
The introduction of metallic self-expandable endoprostheses has changed percutaneous 
biliary stent placement substantially. The self-expandable stents have advantages over 
plastic stents, as they can be introduced on a small delivery catheter, have a large inner 
diameter, and have a fixed position after release. Several types of self-expandable 
endoprostheses are used in biliary stent placement; most percutaneous experience 
concerns the Wallstent (Schneider [Pfizerl, Minneapolis, Minnesota, USA and Bulach, 
This chapter was publisbed as: J Stoker, IS Lameris. Complications of percutaneously inserted biliary 
Wallstenls. J Vase Inlcrven! Radiol1993; 4: 767-772. 
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Switzerland) [1-7]. In many institutions, the Wallstent is preferred over plastic stents 
because percutaneous insertion and reintervention are more easily performed and 
because obstruction by sludge is rare [2-7]. A recent randomized endoscopic study 
comparing use of Wallstents and plastic stents in patients with malignant distal biliary 
obstruction has demonstrated superior patency of the Wallstent [8]. 
Stent-related complications are assessed in 176 patients with malignant biliary 
obstruction who where treated with percutaneous Wallstent endoprostheses in our 
institution. 
6.3 Patients and Methods 
From April 1989 through October 1992, 176 consecutive patients with inoperable 
malignant biliary obstruction treated with use of a total of 207 percutaneously inserted 
Wallstent endoprostheses were studied retrospectively. The study population comprised 
81 men and 95 women, with a median age of 70 years (range, 34-91 years). Median 
survival after stent placement was 95 days (range, 6-1,204 days). Hilar obstruction was 
present in 74 patients, distal obstruction was present in 102 patients; pancreatic 
carcinoma, cholangiocarcinoma and metastatic disease were the main causes 
(Table 6.1). 
Table 6.1 Diagnosis in 176 Patients with Malignant Diliary Obstruction 
Treated with Percutaneously Placed Wallstents 
Hilar Stenosis Distal Stenosis Total 
Diagnosis (n ~ 74) (n ~ 102) (n ~ 176) 
Pancreatic carcinoma 3 70 73 
Choiangiocarcinoma 36 5 41 
Gallbladder carcinoma 15 1 16 
Metastatic disease 13 17 30 
Miscellaneous causes 7 9 16 
Histologic or cytologic confIrmation of the diagnosis was available in 124 patients 
(70%). Among patients with hilar obstruction, 12 had a type I lesion, 13 had a type II 
lesion, 36 had a type 111 lesion, and 13 had a type IV lesion [9]. Endoscopic biliary 
drainage was attempted unsuccessfully in 137 patients (78%). Twenty-nine patients 
(16%) had undergone biliary surgery, and 33 patients (19%) had undergone radiation 
therapy. Thirty patients underwent external radiation therapy directed on the hilum of the 
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liver and the hepatoduodenal ligament; in 20 patients this was combined with 
intraluminal radiation therapy (iridium-I92). Three patients underwent intraluminal 
radiation therapy (Ir-I92) only. 
Technique 
All procedures were performed under sonographic and fluoroscopic guidance. Broad-
spectrum antibiotics were administered 12 hours before and after each procedure. Initial 
catheter drainage is routine at our institution, especially in hilar lesions, with \Vallstent 
insertion after several days. This permits evaluation of the effect of drainage. No stent is 
placed before preexisting cholangitis has disappeared. A 9-F sheath is inserted over the 
guide wire before the delivery catheter is introduced to give an easy access to the biliary 
system. Balloon dilation was performed before stent placement in the first five patients. 
Tllis was abandoned, as the stents continue to expand spontaneously over several days. 
The stent is introduced in compressed form on a 7-F delivery catheter and is released by 
progressive withdrawal of the enclosing membrane. On release, the stent expands and 
shortens. No balloon dilation was performed after stent placement. All stents had a 
maximum diameter of 1 cm after release; length varied from 3.5-10.5 cm. A modified 
Wallstent with improved membrane withdrawal was used in the last five patients. The 
stent or stents had a prepapillary position in 41 patients with a hilar lesion. Twenty-nine 
patients with hilar lesions received more than one stent. Two parallel stents were present 
in 24 patients, while three patients had two segmental stents, which overlapped a 
previously placed stent in the common bile duct. Two right-sided segmental stents, 
which overlapped a third stent in the conunon bile duct, and a long left-sided stent were 
present in two patients. 
Complications 
Early complications were defined as those occurring within 30 days after stent 
placement. Cholangitis was defined as fever above 38°C, in the absence of any other 
explanation. Bleeding was defined as a hemoglobin decrease of 0.5 nunol Fe'+/L or 
more, in the absence of any other explanation. 
A questiolll13ire was send every three months to the patient's physician concerning the 
occurrence of jaundice, fever, or other complications. If complications had occurred, 
further information was obtained from the doctor and from the hospital to which the 
patient was referred. 
The patency period of the stent was considered the interval between the insertion of the 
stent and the time of biliary obstruction, as defmed by means of clinical symptoms, 
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ultrasound (US), and cholangiographic findings. The source of reobstruction was 
determined with US and cholangiographic findings. Obstmction of bile ducts proximal to 
the stent, tumor mass around the proximal end of the stent, and progression of tumor 
mass were used as the main indicators of proximal tumor overgrowth. Distal overgrowth 
was defined as tumor mass around the distal end of the stent and progression of tumor 
mass. Tumor ingrowth was defined as obstruction present at stent level along with 
progression of tumor mass around the stent. 
6.4 Results 
\Vallstent insertion was successful in all patients, although incomplete membrane 
withdrawal of the delivery cathetcr occurred with all stents longer than 6.8 cm. Partial 
release outside the patient with introduction in a long sheath and subsequent release in 
the paticnt solved this problem. Early complications occurred in 12 patients (7%); onc of 
these patients expericnced two early complications (Tablc 6.2). 
Table 6.2 Early Complications in 176 Patients Treatcd with Percutaneously 
Placed Wallstcnts 
Hilar stenosis Distal Stenosis 
Complication (n ~ 74) (n ~ 102) 
Cholangitis 2 4 
Hepatic abscess 1 0 
Reobstruction * 3 1 
Acute cholccystitis * 1 0 
Common bile duct and duodenum 
perforation 0 
Total 8 5 
* One patient with hClllobilia had acute cholecystitis and reobstruction. 
Total 
(n ~ 176) 
6 
1 
4 
1 
13 
Six patients developed cholangitis after insertion, which was serious in two patients. 
Another patient with a hilar lesion had cholangitis aftcr attempted endoscopic biliary 
drainage. Normal routine of initial catheter drainage was abandoned, as ascites was 
present. Ascites was drained percutaneously with \Vallstent insertion at the initial visit; 
he developed an abscess in the undrained right liver lobe and died of sepsis. A patient 
with a hepatocellular carcinoma had persistent hemobilia with acute cholecystitis after 11 
days and Wallstent occlusion after 26 days; both were treated by means of percutaneous 
catheter drainage. Obstruction recurred in three other patients within 30 days. 
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A malpositioned Wallstent caused the death of a patient 21 days after stent placement. 
This patient had two parallel transpapillary Wallstents in the common bile duct and had 
been treated with Ir-192 intraluminal radiation therapy before stent insertion. At autopsy 
only one of the stents was in a transpapillary position; the other had perforated the 
common bile duct and duodenal wall [10]. In a patient with a distal stenosis, pancreatitis 
was aggrevated after an endoscopic attempt at drainage. Septicaemia persisted after 
successful percutaneous biliary drainage. The septicaemia was attributed to the 
pancreatitis and this complication was therefore probably not related to the percutaneous 
procedure. This was confirmed at autopsy. Thirty-day mortality was 12%; deaths were 
related to the procedure in three patients (2%), including a debilitated patient who died 
of a pleural empyema after a transpleural catheter placement. 
Complete follow-up was available in all patients. Late complications other than 
reobstruction occurred in seven patients (4%). Three patients developed acute 
cholecystitis 16 weeks, five months, and 2lYz months, respectively, after stent placement; 
treatment was by percutaneous drainage in two patients and by cholecystectomy in one. 
A duodenal pressure ulcer developed in two patients five weeks and six weeks, 
respectively, after stent insertion. Another patient was admitted six weeks after stent 
placement with melena; because no gastrointestinal bleeding source was found and 
hemobilia could not be excluded, this was attributed to the Wallstent. An abscess 
developed in the right liver lobe of a patient who had initially a type I lesion. The 
abscess was treated by percutaneous drainage. The patient died with sepsis and 
peritonitis. Reobstruction, the major late complication, occurred in 33 patients (19%) 
after a median period of 135 days (range, 6-395 days). Six of these 33 patients had a 
distal obstruction, and 27 had a hilar obstruction. The latter group consisted of five 
patients with a type I lesion, five with a type II lesion, 13 with a type III stenosis, and 
four with a type IV lesion. Obstruction recurred most frequently in patients with a hilar 
Table 6.3 Diagnosis in 33 Patients with Reobstruction after Walls tent Insertion 
Hilar Stenosis Distal Stenosis Total 
Diagnosis (11 ~ 74) (n ~ (02) (n ~ (76) 
Pancreatic carcinoma (n ~ 73) 1 1 2 
Cholangiocarcinoma (n~41) 12 1 13 
Gallbladder carcinoma (11 ~ (6) 7 0 7 
Metastatic disease (n ~ 30) 4 1 5 
Miscellaneous causes (II ~ (6) 3 3 6 
Total 27 6 33 
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Table 6.4 Causes of Reobstruction in 33 Patients Treated with Percutaneously Placed 
Wallsfents 
Hilar Stenosis Distal Stenosis Total 
Cause (n ~ 74) (n ~ 102) (n ~ 176) 
Proximal overgrowth 14 I 15 
Proximal overgrowth and ingrowth I 0 I 
Distal overgrowth 4 0 4 
Tumor ingrowth I I 2 
SteD! angulation I I 2 
Inadequate positioning I 0 I 
Hemobilia I 0 I 
Inadequately functioning Roux loop I 0 I 
No established cause 3 3 6 
Total 27 6 33 
stenosis caused by eholangiocarcinoma or gallbladder carcinoma (Table 6.3). The major 
cause of reobstruction was tumor overgrowth, especially proximal overgrowth (Table 
6.4). Other causes were rare, while sludge did not cause reobstruction in this series. 
Pathologic confirmation was obtained in two patients with tumor ingrowth; in the other 
patients, no attempt was made to obtain histologic or cytologic specimens. 
Reintervention was performed in 25 patients (14% of the total study population, 76% of 
the patients with reobstruction). Seven patients were treated with placement of an 
additional Wallstent (in two, stent placement was combined with catheter drainage), six 
with internal catheter drainage, six with external catheter drainage, three with combined 
internal and external catheter drainage. One patient developed a small liver abscess as a 
sequela of the reobstmction. This abscess was aspirated percutaneously. 
One patient was treated with a plastic endoscopically placed stent because of ascites, 
while another was treated with antibiotics. In both patients symptoms disappeared. 
Endoscopic guide wire manipulation was performed ill one patient, with a short-lasting 
beneficial effect. Reintervention caused complications in four patients (16%). Cholangitis 
occurred in three patients, and a subphrenic fluid collection occurred in one. The 
cholangitis was treated successfully in two patients, while one patient had recurrent 
cholangitis after endoscopical guide wire manipulation. The fluid collection was treated 
by means of percutaneous drainage. 
Nineteen of the 25 patients (76%) who underwent reintervention benefited from the 
procedure; 11 patients remained symptom-free until death. 
Multiple reinterventions for reobstruction were performed in six patients. Twenty-nine 
patients died aner a median period of 61 days (range, 2-523 days) after reobstruction. 
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Four patients are alive, with a median survival of 60 days (range, 30-448 days) afier 
reobstruction. 
6.5 Discussion 
The self-expandable Wallstent endoprosthesis was introduced several years ago in an 
attempt to solve the problem of limited patency of plastic stents due to sludge formation. 
It has become the stent of choice in many institutions, as insertion is more easily 
performed and reobstruction by sludge is rare [2-7]. Although the use of the Wallstent 
for percutaneous stent placement is advantageous, some problems lUay occur during and 
after stent placement. 
Stent release and placement 
The improvement of the delivery catheter design with a hydromer coating between the 
membranes and the introduction of the Unistep system have solved the problems 
encountered with release of stents longer than 6.8 cm. The visibility of the Wallstent at 
fluoroscopy during and after release in obese patients is often poor [7]. Radiographs are 
then needed for adequate delineation of the stent, which is important for accurate place-
ment. The manufacturer is planning to integrate more radiopaque wires in the mesh to 
solve this problem. 
Stent behaviour over time 
After placement, additional shortening and expanding of the stent occurs. The stents 
expand in the common bile duct to or near its maximum diameter. In the hilar region, 
incomplete expansion up to 7 - 8 mm is not unconmlon. The additional expansion after 
release may occur over a long period, which makes stent behaviour somewhat 
unpredictable, especially in complex stent configurations. 
In our first five patients who needed two or more stents, a Y stent configuration was 
used. In three patients with this configuration, at least one of the proximal stents lost 
contact with the distal one, despite an overlap of at least 1.5 cm. This was noticed on 
radiographs taken three weeks to six months after stent placement (Fig. 6.1). Despite the 
disturbed stent configuration, the communication between the dislodged stents remained 
intact. The expanding, shortening, and straightening force of the Wallstent, together with 
respiratory and other movements, cause the filaments at the end of the inner one of two 
stents to climb the mesh of the outer one in a proximal direction, which will lead to a 
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Figure 6.1 Patient with a type III hilar stricture caused by choiangiocarcinoma. (a) Radiograph obtained 
six weeks after placement of three stents in a Y configuration reveals additional shortening of 
the stents with poor alignment. No signs or symptoms of reobslruction were present. 
(b) Acute cholecystitis occurred 21~ months after stent insertion and was treated by means 
of percutaneous gallbladder drainage. Recovery of cystic duct patency is seen on the 
cholecystogram obtained 2112 weeks after drainage. Additional shortening of the stenls is 
visible. with a closer relationship between the stents, 
dislodgement in the direction of the liver hilus (Fig. 6.1). Because of tlus observation the 
use of the Y configuration was abandoned, and currently two parallel Wallstents are 
placed in the hepatocholcdochal duct. In our experience, this is a stable configuration. 
Communication between the paralJel stents remains intact for a long period (Fig. 6.2b). 
Effects 011 allatomical strllctllres 
The Wallstent, as with other biliary stents, has an effect on surrounding tissues. A recent 
histologic study demonstrates mucosal destruction of the bile duct epitheliulll in the early 
phase and nuld-to-moderate fibrosis in the later stages [II]. Qne patient in thls study 
died of perforation of the common bile duct and duodenal wall by one of two parallel 
stents. This patient had undergone intraluminal radiation therapy before stent placement 
[10]. A case of Wallstent erosion through the medial duodenal wall was reported in an 
endoscopic study; no definite cause was reported in that article [12]. 
In our series, two of 135 patients with a transpapillary stent had a duodenal pressure 
ulcer. Intestinal blood loss was the reason for endoscopy in these patients. One 
endoscopic study of 103 patients treated with Wallstents describes two patients with a 
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pressure ulcer [13]. A possible explanation of this phenomenon is a fixed duodenal wall 
opposite a transpapillary stent, causing repetitive trauma of a small area of the 
duodenum. 
Figure 6.2 Type III hilar stricture in a patient with cholangiocarcinoma, which was treated with 
complete drainage by using a right-sided Wallstent Y configuration and a long WaUstent on 
the left. After eight months symptoms recurred. (a) Radiograph demonstrates angling of the 
left-sided Wallstent (arrows indicating angulation). The guide wire indicates the mOre distal 
part of the left hepatic duct. TIle relationship between the right segmental stents and the 
distal stent has changed; one has lost contact with the distal stent. (b) Cholangiogram by the 
left-sided catheter reveals contrast material in right lobe ducts indicating communication 
between the parallel stents. 
The stmcture of the Wallstent allows drainage of the cystic duct through the mesh. 
Impaired drainage through the mesh may occur with tumor progression, sludge, or 
hemobilia. Acute cholecystitis may result, which occurred in four patients in tlus series. 
Hemobilia was the cause in one patient, while in at least one of three other patients it 
was stent related, as repeated cholangiography of the percutaneous cholecystostomy 
revealed recovery of cystic duct patency after 2\1, weeks (Fig 6.lb). 
Stellt oce/usioll 
Stent occlusion by sludge has become a rare cause of reobstruction since the use of 
Wallstents [2-7J. Most cases of reobstmction are now caused by tumor progression, 
especially tumor overgrowth in patients with hilar stricture (Table 6.4). This can be 
prevented in part by proximal overstentillg, but this carries its own limitations and 
disadvantages. First, the number and size of segmental ducts limit the possibilities of 
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sufficient overstenting. Second, a stent will cover side branches which might become 
obstructed due to the stent. Third, reintervention is more difficult when important ducts 
are covered by a Wallstent (Fig. 6.3). One study concerning five patients has reported 
continuous drainage of side branches through the mesh [14]. In our population we also 
noticed small ducts draining through the mesh immediately after placement, but no long-
term results are available [5]. We are reluctant to perform peripheral stent placement as 
the number in the referred study is small and reintervention is hampered. 
Figure 6.3 Incomplete drainage was established through two parallel Wallstents in a patient with a type 
III hilar stricture caused by choiangiocarcinoma. Rcobstruction due to proximal overgrowth 
occurred after I year. (a) Cholangiogram demonstrates segment VIII draining in the left 
hepatic duct through the edge of the left Wallstent. An additional Wallstent was inserted in 
the left hepatic duct because of the overgrowth. (b) A second reintervention was perfonned 
after six weeks because of recurrence of symptoms. External drainage of segment VIII could 
be established, no internal drainage catheter could be passed through the mesh. 
Tumor ingrowth is a recognized phenomenon in Wallstents. The rate of tumor ingrowth 
is influenced by the growth pattern of the tumor, with more ingrowth in cell-rich tumors 
[11]. Ingrowth is, however, not a frequent cause of reobstruction as the inner diameter is 
large and the survival is short. The development of partly or completely coated stents 
may prevent tumor ingrowth, but this will prevent the reported prolonged drainage of 
side branches or the cystic duct through the stent [14]. With adequate stent position and 
length, distal overgrowth appears to be a rare phenomenon. Another potential cause of 
reobstruction is mucosal hyperplasia. The presence of a stent may induce proHferation of 
the wall which may cause reobstmction. Until now this has not been recognized as a 
significant cause of reobstmction in the use of \Vallstents in malignant biliary obstruction 
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[1-8,11]. In this series no reobstruction due to mucosal hyperplasia was diagnosed. 
In addition to an expanding and shortening force, the Walls tent has a force that will 
straighten the stent. This may result in the stent not retaining the often curved shape of 
the bile duct. This will subsequently lead to occlusion of the proximal end of the stent 
by the overlying bile duct wall, as occurred in two patients in this series (Fig. 6.2a) [5]. 
This phenomenon is also reported in the randomised comparitive study of plastic stents 
and Wallstents in malignant distal biliary obstruction [8]. Two cases of reobstruction by 
kinking occurred in that series concerning 49 patients treated by a Wallstent. A large 
angle between the longitudinal axis of the stenosis and the bile duct and the use of a 
relatively short, rigid, large-diameter stent predispose for this phenomenon. This problem 
can be prevented with the use of a longer stent, or a stent with a smaller diameter and 
thereby less expanding force. 
Reintervention should be considered in all cases of reobstruction, as 76% of our patients 
benifited from such a procedure. Several factors should he considered in tius decision, 
such as the clinical condition of the patient and the complexity of the biliary stricture at 
that time. 
In our opinion only tumor ingrowth and impaired stent function due to angUlation and 
incorrect placement can be classified as stent-related causes of reobstruction. All others, 
especially tumor overgrowth, are the result of the expected inevitable progress of the 
tumor. 
Despite some inadequacies, placement of the Wallstent is a safe and well tolerated 
procedure. The most important complication of endoprosthesis insertion in malignant 
biliary obstruction - reobstruction - is predominantly not stent related but is caused by 
the expected progression of the malignant tumor. 
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7 DISCUSSION AND CONCLUSION 
7.1 Introduction 
Endoprostheses have become the treatment of choice in the majority of patients with 
inoperable malignant biliary obstruction [1-7]. Until the late 1980s several types of 
plastic endoprostheses have been used, but all had the major disadvantage of limited 
patency by sludge [8-10]. Several factors were identified infiuencing stent patency, stent 
diameter being a major one [11]. Increase of stent diameter was, however, limited by 
several factors such as more difficult insertion and possibly more complications. A less 
frequent problem was stent migration. 
In the mid and late 1980s the promising design of metallic self-expandable 
endoprostheses prompted their use in biliary stenting to overcome the limitations of the 
plastic endoprostheses. These metal stents have a small delivery catheter, small surface 
area, large diameter after release and fixation against the wall. Most experience with 
metal stents concerns the Wallstent endoprosthesis. The aim of this chapter is to review 
the literature on biliary Wallstents and to determine the place of the percutaneous 
Wallstent in malignant biliary obstruction. 
Since the introduction of the biliary Wallstent in 1988 several uncontrolled studies and 
some controlled studies have been published [12-46]. A review of the literature on 
Wallstents in malignant biliary obstruction is hampered by several factors. Almost all 
studies are non-comparative retrospective studies. These have inherent problems such as 
underscoring of complications while the relationship with the results of the plastic stents 
in the same population remains uncertain. In the majority of studies the results in 
patients with benign and malignant strictures, hilar and distal biliary strictures, or 
different types of metallic stents are presented together without the possibility to convert 
the results to subgroups. Patient selection for percutaneous treatment, as primary 
therapy or only after failed endoscopic drainage, is not always evident. In two of the 
randomized series Wallstent and Strecker stents are used and compared with plastic 
stents. 
This chapter is a modified version of the paper: JS Lameris, J Stoker. Metal stenls for malignant biliary 
obstruction. Digestive diseases 1994; in press, 
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7.2 Insertion and drainage 
The outer diameter of the delivery catheter of a Wal!stent (7-F) is smal!er than the outer 
diameter of a plastic endoprosthesis (12-F). Easier percutaneous insertion of a Wal!stent 
in distal and hilar biliary obstruction is therefore expected and also reported in several 
studies [21,25,39,41]. Although not always appreciated by every radiologist, percutane-
ous placement of large bore polyethylene endoprostheses, which requires mUltiple dilati-
ons, has always been a painful experience for the patient. The ease with which insertion 
of metal stents can be done, has been for many interventionalists the main reason to 
switch from polyethylene to metal stents. Theoretically metal stents can be placed per-
cutaneously in one session, thereby reducing the cost of hospital stay [21,33]. However 
cholangitis, complex biliary strictures, or pending the decision on surgical therapy are 
motives to perform the placement in a two-stage procedure. In case of ascites some 
have advocated the transjugular insertion of a Wal!stent, but ascites drainage or the 
endoscopic route are more obvious [47]. Other less common routes may be used in 
special cases [48]. The stent shortens considerably (up to 40%) during expansion 
[45,49,50]. 
Unlike in percutaneous use, metallic stents have not facilitated the endoscopic placement 
procedure. Although important improvements were carried out, the long delivery 
devices are more prone to mechanical failure. Pre-cut papillotomy may still have to be 
done to enable successful delivery [34]. Inadequate stent release occurred in approxi-
mately 10% of the Wal!stents of the original design [16,18,21,25,33-35,37,45,52]. It 
was caused by inability to retract the enclosing membrane, membrane leak, or by an 
acute angulation of the delivery catheter. The introduction of hydromer coating and the 
Unistep system solved this problem. Difficulty in removing the delivery catheter in hilar 
strictures may be encountered in endoscopic Wal!stent insertion [53]. The funnel-shaped 
flange of the tip of the delivery catheter has a slightly larger diameter than the com-
pressed stent. When no sufficient expansion of the intrahepatic tip of the stent occurs, 
this will prevent catheter withdrawal. TlIis has been reported in stents with the proximal 
tip of the delivery catheter in a smal! intrahepatic duct or a stenotic duct. Mechanical 
failure for other reasons is rare [54]. A new design Wal!stent with gold wires has 
increased the visibility of the stent during fluoroscopy. 
Distal strictures 
Plastic stents or Wallstents have a comparable insertion and initial drainage success rate 
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in distal strictures. The insertion and drainage success rate of plastic stents is approxi-
mately 90-95%. Percutaneous or endoscopic Wallstent insertion is successful in almost 
100% of the patients, while successful drainage will be established in approximately 
95% of the patients [13,18,41]. The two randomized comparative studies confirm these 
uncontrolled studies [34,35]. 
Hila,. strictures 
Successful insertion and drainage is in general more difficult to obtain in hilar stric-
tures. In plastic stents percutaneous placement will be successful in 90% and with 
endoscopy in 50-95%. Inse11ion of the Wallstent is successful in approximately 100% 
[20,21,36,38,39]. Successful drainage will be established in 95-100% of the patients. 
The only comparative study concerning only 20 patients demonstrates successful 
placement of Wallstents in all patients but of plastic stents in eight out of nine patients 
(89%) [36]. The success rates of the stents and techniques will be influenced by the 
choice for complete or incomplete drainage. 
Percutaneous placement of multiple stents in hilar obstruction can easily be done, the 
delivery catheters are first passed through the strictures and then released one after 
another. Ending the two Wallstents next to each other inside the common bile duct is 
well tolerated. Reports on perforation are rare. A Y shaped configuration, as proposed 
by some, has not proved to be always stable [45,55]. Whereas the effect of one lobe 
drainage can be awaited when plastic stents are used, the choice between partial or 
complete drainage is almost irreversible when metal stents are used. Placement of a se-
cond metal stent for the other lobe at a later stage is extremely difficult and in most 
cases impossible. Bilateral endoscopic metal stent placement in hilar lesions is extremely 
difficult and has been reported only occasionally [7,19]. 
A prepapillary position of the distal end of the stents has the advantage of preserving 
the papillary function and minimizing the risk of ascending cholangitis. The outcome of 
reinterventions for obstructed pre-papillary metal stents is not hampered by this 
strategy. 
7.3 Early complications 
Early complications are defined as complications occurring within 30 days after stent 
placement and are generally regarded as procedure-related complications. Cholangitis is 
the most common early complication in palliative biliary stenting with plastic stents as 
91 
Chapter 7 
well as with Wallstents. Stent migration is rare as the stent is fixed against the wall 
after release and becomes embedded in the wall. The histopathological changes produ-
ced by the wires on the bile duct wall consist mainly of focal denudation and mild 
submucosal inflammation with edema [56]. In two months the stent is covered by a 
fibrogranulomatous tissue layer, or in some cases an epithelium-like cell formation 
covers the stent surface. Pressure necrosis, especially related to the edges of the stent, 
has also been noticed and can occasionally lead to perforation of the bile duct and duod-
enal ulcerations [13,55,57]. 
Distal strictures 
The early complication rates of plastic stents and Wallstents are comparable with a 
tendency to a slightly lower early complication rate with Wallstents. 
Table 7.1 Results of Two Prospective Randomized Controlled Trials of Plastic versus Metallic 
Stents for Malignant Distal Biliary Obstruction 
Early complications 
cholangitis 
sten! migration 
cholecystitis 
Thirty-day mortality 
Median survival (days) 
Late obstruction 
sludge 
tumor ingrowth 
sten! migration 
bile duct kinking 
Patency (days) 
median 
mean 
n.a. data not available 
Davids ct al (34) 
Plastic 
(n ~ 56) 
6 (11%) 
5 
Metal 
(n ~ 49) 
6 (12%) 
6 
2 (4%) 7 (14%) 
147 175 
30 (54%) 
29 
16 (33%) 
4 
10 
2 
126 273 
n.a. n.R. 
• including nine patients treated with Strecker stents 
II concerns two patients with a Strecker stcnt 
Knyrim et al (35) 
Plastic 
(n~31) 
1(3%) 
3 (10%) 
n.a. 
12 (39%) 
10 
2 
Metal _ 
(n~31) 
1(3%) 
I 
4 (13%) 
n.a. 
6 (19%) 
2# 
4 
n.a. n.a. 
140 189 
With plaslic endoprostheses early complications occur in approximately 10-20%; with 
early cholangitis being the most frequent early complication (10-15%). The early 
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complication rate with Wallstent endoprostheses is 0-20%, with early cholangitis in 
0-10% [17,21,26,33,37,41]. Bleeding, bile leakage and kinking of the Wallstent are other 
early complications which are rare and partly related to the procedure before Wallstent 
insertion [41,58]. The rare occurrence of early reobstruction is often caused by kinking 
or angling of the Wallstent [34,41]. The two randomized trials report comparable early 
complication rates (Table 7.1) [34,35]. Wallstent migration is rare. 
Hilar strictures 
Early complications occur in 10-20% of the patients with hilar strictures treated by 
\Vallstents. Early cholangitis is the most frequent early complication (5-10%). With 
plastic stents the early complication rate is higher with early cholangitis in 20-30%. 
Complications other than cholangitis with Wallstents are rare [20,21,36,39,59]. 
Migration of a \Vallstent is rare and predominantly occurs during or directly after 
placement [21,24,60,61]. 
7.4 Thirty-day mortality rate and procedure-related mortality rate 
The thirty-day mortality rate for patients with \Vallstent for distal strictures is 5-15% and 
for hilar strictures 5-10% [17-19,21,22,25,26,34-37]. The procedure-related mortality rate 
is 2% for distal and hilar strictures. With plastic stents the results are similar, with a 
thirty-day mortality rate of 10-20% and a procedure-related mortality rate of 1-5%. The 
randomized series on hilar stents gives similar results for both types of stents [36]. The 
two randomized series on \Vallstents in distal strictures give a higher thirty-day mortality 
rate for metal stents [34,35]. In one of those series it could not be explained by stent-
related causes and was not considered to be clinically significant [34]. In the other series 
this difference is not further explained. 
7.5 Late complications 
Reobstruction 
The Wallstent endoprosthesis was introduced to overcome the major drawback of the 
plastic endoprosthesis, namely reobstmction by sludge. This occurs in 20-40% of the 
patients treated by plastic stents, with a median patency of approximately five months in 
distal strictures and three months in hilar strictures. 
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Early results of percutaneous placement were not encouraging and appeared to be no 
better than results with polyethylene stents [12,17). A 40% rate of recurrent jaundice and 
cholangitis was reported, with a median patency of four months in hilar strictures and of 
4.5 months in distal strictures. The use of short vascular stents combined with the 
intrinsic shortening were probably responsible for these disappointing results. Recent 
reports on Wallstents have shown better results (Table 7.2). The data of a large random-
ised comparative endoscopic study of plastic stcnts and \Vallstents are until now only 
reported in an abstract [40). This study comprising 48 patients with hilar strictures and 
115 patients with distal strictures, reports similar reobstruction rates of hoth stCllts 
(13%). The median time to obstruction was 62 days in plastic stents and III days with 
Wallstents. 
Table 7.2 Long Term Results of Treatment of Malignant Biliary Obstruction with Wallstcnts 
Survival Patency rate 
(months) (months) 
No. of Reob-
Authors Ref. Patients Median Mean struction Median Mean 
Gillams et al 1990 (17) 40 40% hilar 4.t 
distal 4.5 
Lammer et al 1990 (t8) 53 11% 
Adam et al 1991 (21) 41 3.4 5% 
Neuhaus et al 1991 (22) 35 3.9 14% - # 
Huibregtse et al 1992 (26) t03 4.7 17 % 4 
Gordon et al 1992 (25) 50 7.5 24 % 5.8 
Dertinger et al 1992 (28) 65 5.1 21 % ·0 
Salomonowitz et al 1992 (3t) 39 4.4 28% 
Stoker et al 1993 * (39) 45 4.5 38 % 5 
Nicholson et at 1993 (37) 77 7.2 9% 
Lee et al 1993 * ,. (38) 22 27% 2.5 
Stoker et al j 993 0 (41) 75 3 5% 5 
Wagner et al 1993 * ,. (36) tl 18% 
Becker et al 1993 * (42) 39 33 % 
* 
only patients with hilar obstruction 
• including a minority of the patients treated by other metal stents 
0 only patients with common duct obstruction 
# stent patency probability 78% after 6.5 months 
0 stellt patency probability 81% after 6 months 
stent patency probability 46% after 12 months 
Experimental studies on \Vallstents, Gianturco-Rosch Z-stent and Palmaz stents have 
demonstrated mucosal hyperplasia of the bile duct wall after s!en! placement [62-65). 
Until now this has not been recognized as a major cause of reobstmction in the clinical 
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usc of Wallstcnts. A histological analysis of bile duct tissue from fifteen patients treated 
by Wallstents has not demonstrated hyperplastic biliary epithelium [56]. 
Distal strictures 
The reobstruction rate and patency rate of \Vallstents in distal strictures are superior to 
plastic stents. Uncontrolled studies of patients with distal strictures or predominantly 
patients with distal strichlres reported a reobstmction rate of 5-15% after approximately 
five months [18,26,30,37,41,42]. The two controlled studies report a higher reobstruction 
ratc (19% and 33%) but also a higher than expected reobstruction rate of plastic stents 
(39% and 54%) (Table 7.1) [34,35]. The polyethylene stents used were 11.5-F and IO-F 
in diameter. Reobstruction in these series occured in the \Vallstent after 6.2 and 7.5 
months and in plastic stents after 4.6 and 3.5 months. These differences in reobstruction 
between plastic stents and \Vallstents were statistically significant in one of these series 
[34]. The results of a percutaneous comparative study on distal strictures have been 
presented as an oral presentation [44]. Reobstruction occurred in 22% (10/46) of the 
patients treated with Wallstents and in 32% (14/44) of the paticnts with plastic Carey-
Coons stents. Median patency of the Wallstent was significantly longer (346 days) than 
of plastic stents (approximately 135 days). Patient selection with differences in survival 
is probably a major cause for the discrepancy between the controlled and the uncon-
trolled studies [34,41]. 
The major cause (approximately 50-60%) of reobstruction of distal Wallstents is tumor 
ingrowth [18,26,27,34,35,37,41,66]. Covering of the stent to prevent this tumor ingrowth 
seems attractive, but no clinical studies on covered \Vallstents in distal strictures have 
been published to date. An cxperimental study in dogs has demonstrated the potential 
usefulness of elastomeric coated Wallstents in the biliary tree [65]. The coated stcnts did 
not migrate in this study and wcre not embedded in the bile duct wall. These stents may 
be removable, which is only an important advantage in stenting of benign strictures. An 
endoscopic study has reported the use of Dacron covered Gianturco stents in four 
patients [67]. In two patients migration of the stent during installment occurred, probably 
because the fixation of a covered stent to the bile duct wall is less firm. An experimental 
shldy on Gianturco stents with several different types of covering demonstrated the 
feasibility of the stents, but mucosal hyperplasia at the ends occurred [64]. The use of a 
half silicon-covered stent with tapered ends prevented this problem. Proximal or distal 
tumor overgrowth is the second most frequent cause of reobstruction. This problem can 
generally be prevented by the use of long stents. Sludge is a minor cause of 
reobstruction. A relatively rare cause of reobstruction is angling or kinking of the bile 
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duct by the straightening force of the stent. Although the Wallstent is flexible, the stent 
is sUbjected not only to a radial recoil force but also to a force that will straighten it. 
This results in a limited pliability along the longitudinal axis which can cause kinking of 
the stent with the bile duct [23,27,34,45,55,68,69]. 
Hilar sh'ictures 
Recurrent jaundice and cholangitis after stent placement is seen more often (20-38%) in 
patients with hilar lesions [21,36,38,39,42]. Wallstent patency will be approximately 
4-5 months but data are very limited (Table 7.2). In one controlled study long-term stent 
failure in patients with hUar lesions who were treated with percutaneously placed metal-
lic stents was 18% vs 50% in polyethylene stents [36]. Although the treatment of pa-
tients with hilar strictures has always been difficult, the difference in results to distal 
stmctures can not be explained by poor stent positioning. The natural course of many 
malignant strictures in the hilar region is characterized by tumor spread along the 
intrahepatic bile ducts. This explains the high incidence of tumor overgrowth, especially 
at the proximal site of the stent [21,36,38,39,45]. The proximal overgrowth might be 
prevented by more proximal overstenting, but this has disadvantages and limitations [45]. 
The anatomical situation often precludes sufficient overstenting, while future 
reintervention might be jeopardized by covering important side branches. The side 
branches may become obstructed by the stent itself, although a study on five patients has 
demonstrated continuous drainage of side branches through the mesh [42,70]. Stent 
malfunction due to tumor ingrowth is relatively less commonly seen in hilar lesions than 
in common bile duct disease [45]. Sludge is a rare cause of reobstmction as well as stent 
angulation [38,45]. The Wallstent has additional expansion after release, which may 
occur over periods of months [45]. This makes stent behavior somewhat unpredictable, 
especially in complex hilar stent configurations. Stent malfunction might theoretically be 
the result of tlus phenomenon. As with plastic stents, reobstruction seems to occur more 
often in lower type hilar strictures and complete drainage [39,71]. This probably reflects 
the longer survival of patients with lower type stricture and complete drainage. Kinking 
is a rare cause of reobstmction. 
Although large comparative studies are lacking the use of Wallstents in hilar strictures 
seems preferable as reobstruction is primarily caused by tumor progression and not by 
stent dysfunction [39]. 
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Rein/erven/ioll 
In case of reobstruction reintervention should be considered, as the majority of the 
patients will benefit from such a procedure [25,45,72]. Certain factors may, however, 
preclude reintervention such as the clinical condition of the patient and the complexity of 
hilar strictures. 
The comparative studies on plastic stents and Wallstents have demonstrated a significant 
lower reintervention rate in the metal stent group [34-36]. 
Metal stents become permanently embedded in the bile duct wall and can not be 
removed. Generally, this does not hamper successful reintervention for stent malfunction. 
It even facilitates percutaneous and endoscopic attempts to restore bile drainage because 
there is no need for stent removal. Although diathermic cleaning, radiotherapy, laser or 
placement of a second metal stent have been advocated, insertion of a polyethylene stent 
or an indwelling catheter has proved to be very effective [19,45,72-75]. Davids et al. 
observed no recurrent jaundice after insertion of a polyethylene stent through a blocked 
stent, whereas after polyethylene stent exchange, the second stent clogged in almost 50% 
of patients [34]. They assumed that friction between the plastic stent and the content of 
the metal stent creates enough space to allow bile flow along even a blocked plastic 
stent. A solution for reobstruction by tumor ingrowth is electrocoagulation which, 
however, has the potential complication of melting and fracture of the stent when the 
probe is in contact with the stent [19,76,77]. Reentering the stent with plastic stents or 
catheters through the mesh after dilating the mesh-holes has been advocated by some, 
but long-term results of these efforts are not known [78,79]. Withdrawal of an occluded 
plastic stent through the mesh Illay not always be an easy procedure [80]. 
Restoring internal bile drainage in hilar disease is more problematic than in distal 
disease. Tumor overgrowth at the proximal edge of the stent is the most common cause 
of recurrent jaundice and in these cases the only option is often a percutaneous 
reintervention. In many cas,es external catheter drainage of obstructed second order bile 
ducts, merely to treat septic complications, is the only realistic treatment. Bilateral 
\Vallstents inserted through a single percutaneous approach may hamper reintervention as 
in plastic stents [20,29,81-83]. 
Other late complications 
Late complications other than reobstruction are rare with \Vallstents. Stent migration was 
a relatively frequent early and late complication with plastic stents. Migration of the 
\Vallstent is, however, very rare and when it occurs this will be during or directly after 
insertion [21,24,61]. The firm fixation against the wall after release and the incorporation 
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in the bile duct wall will prevent migration [56]. Acute cholecystitis caused by the 
Wallstent is rare as with plastic endoprostheses [31,42,45,71,84-86]. The mesh structure 
of the stent will generally allow drainage through the stent wall. This will in general also 
prevent pancreatitis [31,59]. A pressure ulcer of the duodenal wall opposite the stent is 
rare [26,31,45]. 
7.6 Costs 
The use of metal stCllts results in an at least tenfold increase in the cost of the procedure. 
The price of a conventional stent ranges between $60-$160 vs the cost of the Wallstents 
of more than $1000 [87]. However, since reobstruction is encountered less frequently, 
long-term cost reduction is obtained by a decrease in hospital readmissions for stent 
change or insertion of other drainage modalities [34-36]. The three randomized 
comparative studies have demonstrated that the use of the \Vallstent is more economical 
than the use of plastic stents [34-36]. Davids et al. performed an incremental cost 
effectiveness analysis [34]. In this study initial placement of a metal stent in 100 patients 
would have prevented 50 endoscopic procedures for reintervention. The other two 
comparative studies also demonstrated a decrease in the cost of complications when 
metallic stents were used [35,36]. Despite all tIus, the short-term economic 
considerations constitute the major obstacle for widespread use of metal stents. In many 
institutions, the endoscopic use is therefore limited to patients who require second stent 
placement due to blocked plastic stents. 
7.7 Comparison of the Walls tent with other metal stents 
The limited experience with other metal stents and the absence of comparative studies 
precludes a definite comparison between the Wallstent and other metal stents, but some 
advantages and disadvantages can be identified. The major disadvantages of the 
Gianturco-Rosch Z-stent stent are its larger diameter introduction catheter, limited 
longitudinal flexibility and tumor ingrowth between the struts. The costs of the Wallstent 
may thereby also be advantageous compared to the Gianturco-Rosch Z-stent, as in most 
cases one long Wallstent will provide good drainage. With the use of the shorter 
Gianturco-Rosch Z-stent and also the Palmaz stent more than one stent may be required, 
making the Wallstent more economical to use [24]. The rigidity makes the Palmaz stent 
unsuitable for hilar strictures. 
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The stent design most comparable to the \Vallstent is the Strecker stent. The diameter of 
the introduction catheter is 7-F with both systems and both stents are flexible enough to 
allow use in angled segments. An advantage of the Strecker stent compared to the 
\Vallstent is that no shortening oCcurs during release. The Strecker stent has the 
disadvantage of no intrinsic expanding force. Collapse of the endoprosthesis has been 
reported in a considerable number of cases [27]. The reported clinical experience with 
the nitinol coil spring stent is too limited to review its usefulness. Modification of 
several metal stents have been introduced to overcome some disadvantages, such as 
tumor ingrowth, but data are lacking to compare these modified stents with the 
Wallstent. 
The Wallstent has several advantages over other metal stents and is, therefore, the stent 
of choice in percutaneous treatment of malignant biliary obstruction. In the future a 
modified nitinol Strecker stent with intrinsic radial force or a coated Gianturco-Rosch Z-
stent might be alternatives to the \Vallstent. 
A new development in Wallstent design is the partial covered Wallstent [65]. This will 
prevent tumor ingrowth, but may have the disadvantage of occluding the cystic duct or 
segmental bile ducts. There may be a place for a partial coated \Vallstent in distal 
strichlres, as tumor ingrowth is the major cause of reobstmction in these strictures. The 
partial coated Wallstent is not yet available for percutaneous use. 
7.8 Conclusion 
The introduction of the \Vallstent endoprosthesis is a major itmovation in stenting of 
malignant biliary obstruction. Substantial progress has been made in preventing stent 
blockage by sludge with subsequent increased patency rates. However, the Wallstent is 
not the ideal endoprosthesis. The ideal stent for the palliative treatment of malignant bili-
ary obstruction should guarantee easy insertion and relief of jaundice until death [88]. 
Although insertion is facilitated by the \Vallstent, reobstruction remains a significant 
problem. This is predominantly caused by progressive disease. IIll1ovations in stent 
design, such as partly covered stents to prevent tumor ingrowth, may be a further step 
towards the ideal endoprosthesis. The problem of proximal overgrowth by progressive 
disease can only be partially prevented by proximal overstenting and remains a limitation 
of the success of palliative treatment of hilar strictures. 
Although the Wallstent has shortcomings, there are several arguments to support the use 
of this stent rather than conventional endoprostheses. For percutaneous use, the simplifi-
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cation of the placement procedure and the decreased need for reinterventions are of over-
riding importance. An important argument for both percutaneous and endoscopic use is 
the more favourable longterm patency rate, resulting in less readmissions, less 
reinterventions and reduced costs. 
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SUMMARY 
In Chapter 1 the aim of the thesis is defined: namely, to evaluate the efficacy of the 
metallic self-expandable Wallstent endoprosthesis in the percutaneous treatment of 
malignant obstructive jaundice. 
Chapter 2 is an introduction to the important topics in the field of palliative biliary 
drainage. The three major palliative treatment modalities of malignant obstructive 
jaundice are discussed: surgical bypass, and percutaneous or endoscopic endoprosthesis 
insertion. Surgical treatment is generally performed in patients with potentially 
resectable tumors, or in patients with duodenal obstruction. Most patients will undergo 
non-surgical techniques employing plastic endoprostheses. 
The major drawback to the use of plastic stents is reobstruction caused by sludge 
blocking the stent, necessitating reintervention. Several factors influencing patency such 
as stent inner diameter, stent surface area, stent material, and stent design are 
discussed. Recent studies using optimized plastic stents are described which report a 
reobstruction rate of 20-40%, with a median patency of approximately five months in 
distal strictures and approximately three months in hilar strictures. Stent migration is a 
less conunon, but significant, drawback in the use of plastic stents. 
Against this background of scepticism regarding the use of plastic stents, interest in the 
use of metal expandable stents in biliary stenting has increased. These stents have the 
advantage of a small diameter introduction catheter, a large diameter after release, fixed 
position after release, and a small surface area. The experience with expandable biliary 
stents predominantly concerns the self-expandable Wallstent endoprosthesis. The 
percutaneous use of this stent is the subject of this thesis. 
Our initial results with the percutaneously inserted Wallstent endoprosthesis in 69 
patients with malignant biliary obstruction are described in Chapter 3. A distal stricture 
was present in 41 patients and a hilar stricture was present in 28 patients. The results of 
the Wallstent with regard to reobstruction by sludge were encouraging, as this did not 
occur. The problem of reobstruction was, however, not solved as tumor ingrowth, and 
especially tumor overgrowth, were recognized causes of reobstruction. In distal 
strictures reobstruction occurred in 2 of 41 patients (5%) after 6 and 12 months, 
respectively. Reobstruction occurred after a median period of 3.6 months in 8 of 28 
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patients (29%) with hilar strictures. Use of Wallstents with sufficient length is 
important. First because the Wallstent will shorten while expanding, and second because 
long stents will prevent kinking of the bile duct by the straightening force of the 
Wallstent. 
In Chapter 4, results of the percutaneously inserted Wallstent in 45 patients with hilar 
strictures are described. Wanstents were easier to insert than plastic endoprostheses. as 
the outer diameter of the introduction catheter is smaller than the outer diameter of 
plastic stents (7-F vs 12-F). Percutaneous placement of more than one stent in hilar 
strictures is easier perfOlmed with Wallstents than with plastic stents. 
Reobstruction occurred in 17 of the 45 patients (38%) after a median period of five 
months. The major cause of reobstruction was proximal tumor overgrowth by 
progressive disease. This problem can only be partially prevented by overstenting and 
remains a limitation to the success of palliative biliary drainage. No reobstruction by 
sludge occurred. Reintervention was performed in 14 patients (31 %); this was easier 
than with plastic stents. as no stent removal was needed. Because stent insertion and 
reintervention are easier. and reobstruction is not primarily stent-related, the 
percutaneous use of the Wallstent in hilar strictures is preferred to plastic stents. 
Chapter 5 presents our results in 75 patients with distal strictures. As in hilar strictures, 
insertion and reintervention were easier with the Wallstent than with plastic stents. 
Reobstruction was rare: occurring in four patients after 21, 127, 176, and 341 days, 
respectively. Tumor ingrowth was the cause of reobstruction in one patient and bile duct 
kinking by the stent in another patient. The cause was not established in two patients. 
With the use of the Wallstent, definitive palliative biliary drainage could be established 
in the majority of patients with distal strictures. 
The limitations and complications of the percutaneously inserted Wallstent 
endoprosthesis in 176 patients with malignant obstructive jaundice are discussed in 
Chapter 6. Changes in design have solved initial problems with visibility of the stent 
during fluoroscopy and stent release of the introduction catheter. Additional expansion 
of the stent after release makes stent behavior over time somewhat unpredictable, 
especially in complex stent configurations. For this reason, two parallel stents should be 
used when more than one Wallstent is needed; in our experience this has proved a 
stable configuration. Effects of the stent on surrounding structures generally remain 
restricted to early mucosal destruction and. later, fibrosis. However, in one patient bile 
108 
Sununary 
duct perforation occurred, while a duodenal pressure ulcer developed in two other 
patients. The mesh structure of the stent allows drainage of bile ducts and cystic duct 
through the stent wall, but tumor progression may interfere with this drainage. In this 
extended study population, the causes and the occurrence rate of reobstruction are 
similar to those in the smaller study population described in the previous three chapters. 
A review of the literature addressing the Wallstent in malignant obstructive jaundice is 
discussed in Chapter 7. Our results, described in Chapters 3-6, are for the most part 
confirmed by the results reported in the literature. 
Early published experience with the Wallstent endoprosthesis with regard to 
reobstruction was disappointing as jaundice recurrence and cholangitis occurred in 40% 
of the patients, with a median patency of 4.5 months in distal strictures and 4 months in 
hilar strictures. More recent studies, using longer stents, have demonstrated the 
superiority of the Wallstent endoprosthesis. Numerous uncontrolled series have reported 
the occurrence of reobstruction after approximately five months in 5-15 % of the patients 
with distal biliary strictures treated by Wallstents. The reobstruction rates of plastic 
stents and Walls tents in randomised studies are higher: approximately 45% and 25%, 
respectively. With plastic stents reobstruction occurs in these series after approximately 
four months and with Wallstents after seven months. The major cause of reobstruction 
is tumor ingrowth through the mesh of the stent. This problem may be prevented in the 
future by covered stents. Data on patients with hilar strictures are limited, but also 
indicate a more favorable patency of the Wallsten!. The major cause of reobstruction in 
this group of patients is tumor overgrowth by progressive disease, which can only be 
partial prevented by overstenting. The reintervention rate in the reported studies is 
lower for Wallstents than for plastic stents, while reintervention is facilitated as there is 
no need for stent removal. The limited reported experience with other metal stents 
precludes a definite comparison, but the results with the Wallstent seem favorable. 
The only major drawback of the Wallstent is the higher short-term costs. The overall 
costs are, however, reduced as the more favorable patency rate results in less 
readmissions, less reinterventions and, therefore, reduced long-term costs. 
There were no major differences between our results and those reported in the 
literature. The somewhat unpredictable stent behavior in complex stent configurations 
is, however, rarely described. This is probably due to the small number of studies 
concerning patients with hilar biliary strictures. These patients are thereby commonly 
treated by one stent. Kinking of the hepatocholedochal duct is also seldom reported. 
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The Wallstent endoprosthesis is for several reasons the stent of choice in the 
percutaneous palliative treatment of malignant obstructive jaundice. First, insertion and 
reintervention are easier performed. Second, the reobstruction rate is decreased and 
reobstruction is mainly due to non stent-related causes. Finally, the overall costs over 
time are decreased. 
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In !lOofdstuk 1 wordt het doel van dit proefschrift beschreven, het beoordelen van de 
effectiviteit van de percutaan geplaatste Wallstent endoprothese bij de palliatieve 
behandeling van patienten met maligne obstruktie-icterus. 
Hoofds/llk 2 is een beschrijving van de belangrijkste onderwerpen bij de palliatieve 
behandeling van maligne galwegobstruktie. De drie belangrijkste behandelingsvormen 
worden beschreven: chirurgische bypass en percutaan of endoscopisch geplaatste 
endoprothesen (stents). De chirurgische behandeling wordt toegepast bij mogelijk 
cUl'atief te behandelen patienten en bij patienten met duodenumobstruktie. De 
meerderheid van de patienten zal echter met niet-chirurgische geplaatste endoprothesen 
worden behandeld. 
Het grootste nadeel van endoprothesen is het optreden van recidieficterus door 
verstopping van de endoprothese met galmodder. Dit maakt veelal het plaatsen van een 
nieuwe stent noodzakelijk. Verschillende factoren die van invloed zijn op het ontstaan 
van verstopping van de endoprothese door galmodder worden vervolgens in dit 
hoofdstuk beschreven. Het gaat hierbij om de inwendige diameter van de stent, het stent 
oppervlak, het stent materiaal en het ontwerp van de stent. Recente onderzoekingen met 
de beste plastic endoprothesen melden een re-obstruktie percentage van 20-40% na een 
mediane interval van ongeveer vijf maanden bij distale tumoren; bij hilaire tumoren 
bedroeg dit drie maanden. Een minder frequent probleem bij het gebruik van plastic 
endoprothesen is dislokatie van de stent. 
Gezien de tegenvallende resultaten met plastic endoprothesen, ontstond er een 
toenemende belangstelling voor het gebruik van metalen expanderende endoprothesen in 
de galwegen. Deze endoprothesen hebben het voordeel van een kleine diameter van de 
introduktiecatheter. cen grote diameter van de stent na plaatsing. cell gefixeerde positie 
van de stent tegen de wand en een klein stent oppervlak. De ervaring met dit type stents 
is voomamelijk opgedaan met de zelfexpanderende Wallstent endoprothese. De 
percutane toepassing van deze endoprothese is het onderwerp van dit proefschrift. 
Ooze eerste ervaringen met de percutaan geplaatste Wallstent endoprothese bij 69 
patienten met maligne galwegobstruktie worden beschreven in hoofds/uk 3. De 
resultaten van de Wallstent met betrekking tot het optreden van re-obstruktie door 
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galmodder waren bemoedigend, re-obstruktie door galmodder trad niet op. Het 
v66rkomen van re-obstruktie was daarmee niet geheel verholpen, omdat tumoringroei en 
bij hilaire tumoren met name tumorovergroei re-obstruktie veroorzaakten. Bij distale 
stenosen trad re-obstruktie op bij 2 van de 41 patienten (5%) na respectievelijk 6 en 12 
maanden. Bij hilaire stenosen trad re-obstruktie op bij 8 van de 28 patienten (29%) na 
een mediane periode van 3,6 maanden. Het is belangrijk dat Wanstents met een 
voldoende lengte worden gebruikt. Ten eerste wordt de stent korter tijdens de expansie 
en ten tweede wordt op deze wijze voorkomen dat de galweg "kink!" door de 
longitudinale kracht van de Wanstent. 
In hoofdslllk 4 worden de resu!taten van de percutaan geplaatste Wanstent bij 45 
patienten met hilaire galwegstenosen beschreven. Het plaatsen van de Wanstent was 
gemakkelijker dan het plaatsen van een plastic stent, omdat de buitendiameter van de 
introduktiecatheter van de Wanstent kleiner is dan de buitendiameter van een plastic 
endoprothese (7-F versus 12-F). Tevens is de percutane plaatsing van meerdere 
endoprothesen gemakkelijker uitvoerbaar met Wanstent endoprothesen dan met plastic 
stents. 
Re-obstruktie trad op bij 17 van de 45 patienten (38%) na een mediane periode van 5 
maanden. De belangrijkste oorzaak van re-obstruktie was proximale tumorovergroei 
door tumorprogressie. Dit probleem is maar ten dele door het gebruik van langere stents 
(overstenten) te voorkomen. Dit vormt derhalve een beperking van palliatieve galweg-
drainage. Er trad geen re-obstruktie ten gevolge van galmodder op. Re-interventie was 
noodzakelijk bij 14 patienten (31 %). Dit was gemakkelijker uitvoerbaar dan met plastic 
stents, die irnrners eerst moeten worden verwijderd. 
Bij de percutane behandeling van hilaire stenosen heeft de Wanstent endoprothese om 
bovengenoemde redenen de voorkeur boven de plastic endoprothese. 
In "oofdstuk 5 worden onze resuHaten bij 75 patienten met distale galwegstenosen 
beschreven. Ook bij deze patientengroep is plaatsing en re-interventie gemakkelijker dan 
met plastic stents. Re-obstruktie kwam sporadisch voor, namelijk bij vier patienten na 
respectievelijk 21, 127, 176 en 341 dagen. Tumoringroei was de oorzaak van re-
obstruktie bij een patient en "kinken" van de galweg door de stent bij een andere 
patient. Bij de twee andere patienten werd de oorzaak niet vastgesteld. Met de Wanstent 
endoprothese kon bij de meerderheid van de patienten een probleemloze palliatieve 
galwegdrainage worden bewerkstelligd. 
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De beperkingen en de complicaties van de percutaan geplaatste Wallstent endoprothese 
bij 176 patienten met maligne hilaire of distale galwegobstruktie worden beschreven in 
IlOofdstuk 6. De aanvankelijk aanwezige problemen met de zichtbaarheid van de stent 
tijdens rontgendoorlichting en het loslaten van de stent van de catheter tijdens plaatsing, 
zijn inmiddels door wijzigingen in het ontwerp verdwenen. De voortgaande expansie 
van de stent na plaatsing zorgt voor een wat unvoorspelbaar stentgedrag, met name bij 
complexe stentconfiguraties. Om deze reden verdient het de voorkeuf, indien meerdere 
stents geplaatst dienen te worden, twee parallelle stents te gebruiken. Dit is een stabiele 
stentconfiguratie gebleken. Effekten van de stent op omgevende structuren blijven veelal 
beperkt tot destruktie van de mucosa in een vroeg stadium en fibrosering in een later 
stadium. Bij een patient trad galwegperforatie op. Bij twee patienten was sprake van een 
duodenumdrukulcus ten gevolge van de stent. Drainage van zijtakken van de galwegen 
en ductus cysticus is mogelijk door de mazen van de stent. Tumorgroei kan dit echter 
verhinderen. In de patientenpopulatie beschreven in dit hoofdstuk waren de oorzaken en 
de frekwentie van re-obstruktie ongeveer gelijk aan de kleinere patientenpopulatie 
beschreven in de vorige drie hoofdstukken. 
Een literatuuroverzicht van de resultaten van de Wallstent bij maligne galwegobstruktie 
is het onderwerp van hoofdstuk 7. In de literatuur worden onze ervaringen met de 
Wallstent, zoals beschreven in de hoofdstukken 3 tot en met 6, grotendeels bevestigd. 
De eerste gepubliceerde ervaringen met de Wallstent endoprothese met betrekking tot 
het optreden van re-obstruktie waren teleurstellend. Recidieficterus en cholangitis traden 
op bij 40% van de patienten met een mediane interval van 4,5 maanden bij distale 
tumoren en 4 maanden bij hilaire tumoren. Recenter onderzoek, waarbij langere stents 
werden gebruikt, heeft echter aangetoond dat re-obstruktie minder vaak optreedt. Een 
groot aantal niet-vergelijkende studies melden optreden van re-obstruktie na ongeveer 
vijf maanden bij 5-15% van de patienten met distale galwegtumoren. Vergelijkende 
gerandomiseerde studies melden hogere re-obstruktie percentages van zowel plastic 
stents als Wallstents, namelijk 45% en 25%. De re-obstruktie treedt op na vier maanden 
bij plastic stents en na zeven maanden bij Wallstents. De belangrijkste oorzaak van re-
obstruktie blijkt tumoringroei door de mazen van de stent te zijn. Het gebruik van 
beklede stents zal dit probleem mogelijk doen afnemen. De literatuurgegevens over de 
Wallstent bij patienten met hilaire tumoren zijn beperkt, maar wijzen ook op een minder 
vaak optreden van re-obstruktie dan bij plastic stents. De belangrijkste oorzaak voor re-
obstructie bij deze groep patienten is tumorovergroei door progressie van de ziekte. Het 
gebruik van langere stents (overstenten) kan dit probleem maar ten dele voorkomen. Vit 
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verschillende studies blijkt dat re-interventie minder vaak noodzakelijk is bij patienten 
met Wallstents dan met plastic stents. De re-interventie wordt daarbij vereenvoudigd, 
omdat geen endoprothese verwijdering nodig is. De gepubliceerde ervaring met andere 
typen metalen stents is te beperkt voor een grondige vergelijking. De resultaten van de 
Wallstent endoprothese ten opzichte van andere expanderende stents lijken echter 
vooralsnog gunstig. 
Het enige belangrijke nadeel van de Wallstent, zowel in onze eigen ervaring als in de 
literatuur, is gelegen in de initieel hogere kosten. De totale kosten per patient zijn echter 
lager, doordat het minder vaak optreden van re-obstmktie minder ziekenhuisopnamen en 
minder re-interventies tot gevolg heeft. 
Belangrijke verschillen tussen onze bevindingen en de literatuur zijn niet aanwezig. WeI 
wordt het door ons gevonden wat onvoorspelbare stentgedrag bij complexe stent-
configuraties nauwelijks beschreven. Dit word! waarschijnlijk veroorzaalet door het 
gering aantal studies met patienten met hilaire galwegstenosen, die dan daarbij veelal 
met een stent worden behandeld. Oak het "kinken" van de ductus hepatocholedochus ten 
gevolge van de stent wordt weinig beschreven. 
De Wallsten! endoprothese is am verschillende redenen de endoprothese van eerste 
keuze bij de percutane behandeling van maligne obstructie-icterus. Plaatsing en re-
interventie zijn gemakkelijker uitvoerbaar, het re-obstruktie percentage is kleiner en de 
totale kosten per patient zijn lager. 
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NAWOORD 
Het schrijven van een proefschrift is een inspanning waaraan velen een bijdrage leveren. 
Met name wi! ik daarvoor bedanken: 
Renee, die mij de ruimte heeft gegeven om dit proefschrift te schrijven. Vele 
geplande IVandelingen gingen ten gevolge van het schrijven van dit proefschrift 
niet door. De LAW/GR 5 naar Nice moet op ons drieen (vieren, .... ) IVachten. 
Prof. dr. J.S. Lameris, die mij de mogelijkheid heeft gegeven de in ons 
ziekenhuis verkregen ervaring met de percutaan geplaatste Wallstent 
galIVegendoprothese te verwerken tot dit proefschrift. Zonder zijn kennis en 
ervaring zou dit proefschrift niet zijn geschreven. 
Prof. dr. H.E. Schlitte, voor het kritisch doorlezen van het manuscript en het 
motiveren tijdens "de laatste loodjesn • 
Prof. dr. J. Jeekel, drs. M. van Blankell5tein, dr. Ch.L. Zollikofer, 
Prof. dr. D.J. Gouma en dr. K. Huibregtse voor het zitting nemen in de 
promotiecommissie. 
De heer A.W. Zwamborn en mevrouw M.G. A.M. van der Lee, voor het 
vervaardigen van de lay-out. 
Mevrouw K. Schoenmaker, voor het uitwerken van de diverse publica ties. 
De heer T. Rijsdijk, voor het vervaardigen van de foto's. 
Mevrouw drs. I L. Tan, voor het kritisch doorlezen van het manuscript. 
Mevrouw L. Visser-Isles, voor het corrigeren van de Engelse tekst. 
De vele polikliniek assistentes, secretaresses en artsen in eerr groat aantal 
ziekenhuizen, die ik de afgelopen jaren heb lastig gevallen om de gegevens van 
de in dit proefschrift beschreven patienten te completeren. 
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